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Abstract 
Matching local muscle O2-supply to O2-demand during the prodigious exercise-induced 
metabolic challenge is achieved through coordinated mechanisms of vascular control. The 
unique sensitivity of ATP-sensitive potassium (KATP) channels to cell metabolism indicates the 
potential to match energetic demand to peripheral O2 transport. The aim of this dissertation was 
to determine the magnitude and kinetics of the KATP channel contribution to vascular control 
during exercise in health and heart failure. It was hypothesized that KATP channel inhibition via 
glibenclamide would, in healthy rats, 1) reduce exercising skeletal muscle blood flow and 
vascular conductance 2) speed the fall of microvascular O2 driving pressure (PO2mv; set by the 
O2 delivery-O2 utilization ratio) during muscle contractions and 3) in heart failure rats, augment 
the PO2mv undershoot and delay the time to reach the contracting steady-state. A total of 55 
male Sprague-Dawley rats were used under control and glibenclamide conditions (5 mg kg-1). 
Hindlimb muscle blood flow (radiolabelled microspheres) was determined at rest (n = 6) or 
during treadmill exercise (n = 6-8; 20, 40 and 60 m min-1, 5% incline). Spinotrapezius muscle 
PO2mv (phosphorescence quenching) was measured in 16 heart failure (coronary artery ligation) 
and 12 healthy rats and during 180 s of 1-Hz twitch contractions (~6 V). The major effects of 
glibenclamide were, in healthy rats, 1) a reduction in exercising hindlimb skeletal muscle blood 
flow with the greatest effect in predominantly oxidative muscle fiber types and at higher running 
speeds 2) an increased prevalence of the undershoot of PO2mv steady-state and doubled time to 
reach the steady-state and 3) in heart failure rats, a reduced baseline PO2mv, an augmented 
undershoot of the steady-state and time to reach steady-state and a reduction in the mean PO2mv 
during contractions. These data suggest that the KATP channel contributes substantially to 
exercise-induced hyperemia and may contribute to the slowing of VO2 kinetics given the spatial 
  
and temporal effects of glibenclamide. The KATP channel-mediated protection against a severe 
O2-delivery to O2-utilization mismatch at the onset of contractions raises serious concerns for 
sulphonylurea treatment in diabetes which is likely to cause perturbations of [metabolite] and 
compromise exercise tolerance. 
 
  
  
VASCULAR ATP-SENSITIVE POTASSIUM CHANNELS IMPACT SPATIAL AND 
TEMPORAL OXYGEN TRANSPORT:  
IMPLICATIONS FOR SULPHONYLUREA THERAPY 
 
 
by 
 
 
CLARK THOMAS HOLDSWORTH 
 
 
B.S., State University of New York at Cortland, 2009 
M.S., Kansas State University, 2013 
 
 
A DISSERTATION 
 
 
submitted in partial fulfillment of the requirements for the degree 
 
 
DOCTOR OF PHILOSOPHY 
 
 
 
Department of Anatomy and Physiology 
College of Veterinary Medicine 
 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
 
2015 
 
 
 
 
Approved by: 
 
Major Professor 
Dr. Timothy I. Musch 
  
  
Copyright 
CLARK THOMAS HOLDSWORTH 
2015 
  
  
Abstract 
Matching local muscle O2-supply to O2-demand during the prodigious exercise-induced 
metabolic challenge is achieved through coordinated mechanisms of vascular control. The 
unique sensitivity of ATP-sensitive potassium (KATP) channels to cell metabolism indicates the 
potential to match energetic demand to peripheral O2 transport. The aim of this dissertation was 
to determine the magnitude and kinetics of the KATP channel contribution to vascular control 
during exercise in health and heart failure. It was hypothesized that KATP channel inhibition via 
glibenclamide would, in healthy rats, 1) reduce exercising skeletal muscle blood flow and 
vascular conductance 2) speed the fall of microvascular O2 driving pressure (PO2mv; set by the 
O2 delivery-O2 utilization ratio) during muscle contractions and 3) in heart failure rats, augment 
the PO2mv undershoot and delay the time to reach the contracting steady-state. A total of 55 
male Sprague-Dawley rats were used under control and glibenclamide conditions (5 mg kg-1). 
Hindlimb muscle blood flow (radiolabelled microspheres) was determined at rest (n = 6) or 
during treadmill exercise (n = 6-8; 20, 40 and 60 m min-1, 5% incline). Spinotrapezius muscle 
PO2mv (phosphorescence quenching) was measured in 16 heart failure (coronary artery ligation) 
and 12 healthy rats and during 180 s of 1-Hz twitch contractions (~6 V). The major effects of 
glibenclamide were, in healthy rats, 1) a reduction in exercising hindlimb skeletal muscle blood 
flow with the greatest effect in predominantly oxidative muscle fiber types and at higher running 
speeds 2) an increased prevalence of the undershoot of PO2mv steady-state and doubled time to 
reach the steady-state and 3) in heart failure rats, a reduced baseline PO2mv, an augmented 
undershoot of the steady-state and time to reach steady-state and a reduction in the mean PO2mv 
during contractions. These data suggest that the KATP channel contributes substantially to 
exercise-induced hyperemia and may contribute to the slowing of VO2 kinetics given the spatial 
  
and temporal effects of glibenclamide. The KATP channel-mediated protection against a severe 
O2-delivery to O2-utilization mismatch at the onset of contractions raises serious concerns for 
sulphonylurea treatment in diabetes which is likely to cause perturbations of [metabolite] and 
compromise exercise tolerance. 
 
 
 
viii 
Table of Contents 
 
List of Figures ................................................................................................................................ xi	
List of Tables ................................................................................................................................ xii	
Dedication .................................................................................................................................... xiii	
Chapter 1 - Background .................................................................................................................. 1	
References ................................................................................................................................... 3	
Chapter 2 - Acute blockade of ATP-sensitive K+ channels impairs skeletal muscle vascular 
control in rats during treadmill exercise .................................................................................. 6	
Abstract ....................................................................................................................................... 6	
Introduction ................................................................................................................................. 7	
Methods ...................................................................................................................................... 9	
Ethical approval ...................................................................................................................... 9	
Surgical instrumentation ....................................................................................................... 10	
Experimental protocol ........................................................................................................... 10	
Determination of BF and VC ................................................................................................ 11	
Statistical analysis ................................................................................................................. 12	
Results ....................................................................................................................................... 13	
Effects of GLI on HR, MAP, arterial blood gases, pH, hematocrit, [lactate] and [glucose] 13	
Effects of GLI on skeletal muscle BF and VC ..................................................................... 13	
Effects of GLI on renal and splanchnic BF and VC at rest and during exercise .................. 14	
Discussion ................................................................................................................................. 15	
Experimental considerations ................................................................................................. 20	
Conclusions ........................................................................................................................... 22	
References ................................................................................................................................. 30	
Chapter 3 - Modulation of rat skeletal muscle microvascular O2 pressure via KATP channel 
inhibition following the onset of contractions ....................................................................... 36	
Abstract ..................................................................................................................................... 36	
Introduction ............................................................................................................................... 37	
Methods .................................................................................................................................... 39	
ix 
Ethical approval .................................................................................................................... 39	
Drugs ..................................................................................................................................... 39	
Surgical instrumentation ....................................................................................................... 40	
Experimental protocol ........................................................................................................... 41	
Spinotrapezius PO2mv measurement .................................................................................... 41	
Analysis of spinotrapezius PO2mv kinetics .......................................................................... 42	
Statistical analysis ................................................................................................................. 44	
Results ....................................................................................................................................... 45	
Arterial blood samples and cardiovascular hemodynamics .................................................. 45	
Spinotrapezius PO2mv .......................................................................................................... 45	
Discussion ................................................................................................................................. 47	
KATP channel inhibition and cardiovascular hemodynamics ................................................ 47	
KATP channel inhibition and spinotrapezius PO2mv ............................................................. 48	
Implications for sulphonylurea therapy ................................................................................ 50	
Experimental considerations ................................................................................................. 51	
Conclusions ........................................................................................................................... 53	
References ................................................................................................................................. 57	
Chapter 4 - Vascular KATP channels reduce severe muscle O2-delivery to O2-utilization mismatch 
during contractions in chronic heart failure rats .................................................................... 64	
Abstract ..................................................................................................................................... 64	
Introduction ............................................................................................................................... 65	
Methods .................................................................................................................................... 67	
Ethical approval .................................................................................................................... 67	
Myocardial infarction procedures ......................................................................................... 67	
Surgical instrumentation ....................................................................................................... 68	
Drugs ..................................................................................................................................... 69	
Experimental protocol ........................................................................................................... 70	
Spinotrapezius PO2mv measurement .................................................................................... 71	
Analysis of spinotrapezius PO2mv kinetics .......................................................................... 72	
Results ....................................................................................................................................... 74	
Discussion ................................................................................................................................. 76	
x 
References ................................................................................................................................. 84	
Chapter 5 - Summary .................................................................................................................... 92	
  
xi 
List of Figures 
Figure 1-1. GLI increased MAP (A) at rest and during submaximal exercise at 20, 40 and 60 m 
min-1 while HR (B) was decreased at rest and 20 m min-1.  *, p < 0.05 versus control. ....... 27	
Figure 1-2. GLI decreased total hindlimb skeletal muscle BF (A) and VC (B) during submaximal 
exercise at 20, 40 and 60 m min-1 but not at rest compared to CON.  *, p < 0.05 versus 
control. .................................................................................................................................. 28	
Figure 1-3. The percent decreases in exercising hindlimb VC with GLI were positively correlated 
with the percent type I and type IIa fibers of the muscles or muscle portions for at speeds of 
20 (A), 40 (B) and 60 (C) m min-1. p < 0.05 versus control. ................................................ 29	
Figure 2-1. Spinotrapezius PO2mv averages for 180 s post-control (open circles) and post-GLI 
(closed circles) infusion. The peak PO2mv was significantly greater with GLI but not 
control. .................................................................................................................................. 55	
Figure 2-2. Spinotrapezius PO2mv profiles and kinetics representations. .................................... 56	
Figure 3-1. Spinotrapezius PO2mv profiles and kinetics representations. .................................... 83	
 
  
xii 
List of Tables 
Table 1-1. Effects of GLI on individual hindlimb skeletal muscle BFs (ml min-1 (100 g)-1) and 
VCs (ml min-1 (100 g)-1 mmHg-1) for the rest group ............................................................ 23	
Table 1-2. Effects of GLI on individual hindlimb skeletal muscle BFs for exercise groups ....... 24	
Table 1-3. Effects of GLI on individual hindlimb skeletal muscle VCs for exercise groups ....... 25	
Table 1-4. Effects of GLI on BF (ml min-1 (100 g)-1) and VC (ml min-1 (100 g)-1 mmHg-1) in the 
kidneys and organs of the splanchnic region for rest and exercise groups. .......................... 26	
Table 2-1. Spinotrapezius PO2mv parameters at rest and following the onset of contractions 
under control and GLI (5 mg/kg) conditions. ....................................................................... 54	
Table 3-1. Morphological and hemodynamic characteristics of CHF rats. .................................. 81	
Table 3-2. Spinotrapezius PO2mv parameters at rest and following the onset of contractions 
under control, GLI and PIN conditions. ................................................................................ 82	
 
  
xiii 
Dedication 
Dedicated to my loving parents William and Marcia Holdsworth, my brother Neil 
Holdsworth and the memory of my cousin Lauren Miller.  
 
  
1 
Chapter 1 - Background 
Noma et al. first demonstrated the presence of KATP channels in cardiac myocytes over 
three decades ago (Noma, 1983). In cardiac myocytes they were able to measure a K+ efflux that 
was sensitive to both the application of ATP and ADP. However, KATP channel research is most 
commonly associated with the channel function in pancreatic beta cells (Ashcroft et al., 1984). 
The discovery that KATP channels could couple glucose-induced metabolism increases to insulin 
release led directly to the pharmacological progress underlying the treatment of diabetes 
mellitus. The early realization of the potential for KATP channel exploitation in diabetes mellitus 
was foundational to the multi-fold increase in the search for channel activators and inhibitors. 
Inhibitors ranged widely from first generation tolbutamide to the recent use of the 
sulphonlyureas glipizide and glibenclamide. The channel activators are diverse and include the 
benzothiadiazine, diazoxide, and the cyanoguanidine, pinacidil. The differences in function 
appear to be related to a varying affinity for the diverse isoforms of KATP channel proteins (Quast 
et al., 1994). 
The structure and function of the KATP channel is complex and not completely 
understood. I will limit the subsequent discussion to the characteristics of the vascular KATP 
channel. Each KATP channel consists of the four pore forming units Kir6.1 and the four subunits 
SUR2B. The pore forming unit appears to be the main site for the binding of 4 ATP molecules 
independently and non-cooperatively which results in steep inhibitory dependence and can be 
achieved with non-hydrolyzable analogs suggesting that the energy from ATP hydrolysis is not 
requisite for channel inhibition. The pore tetramer is a standard K+ inward rectifier which 
consists of two transmembrane helical domains, TMD1 and TMD2, and cytoplasmic NH2 and 
COOH termini. The four SUR2B subunits are ATP binding cassette proteins arranged in a 
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heteromeric octamer with the Kir6.1 pore forming units. Pinacidil is a potent activator of the 
SUR2 isoforms compared to diazoxide which targets SUR1.  
The first instances of KATP channel block in vascular smooth muscle were observed by 
Nelson and colleagues in 1990 in rabbit mesenteric arteries (Nelson et al., 1990). The results 
were expanded to demonstrate vascular depolarization, vasoconstriction, and attenuated 
functional sympatholysis during KATP channel block (Beech et al., 1993; Mori et al., 1995; 
Thomas et al., 1997). Within the field of exercise physiology these investigations were 
transitioned to skeletal muscle vascular beds. KATP channel block was shown to reduce the 
forearm hyperemic response to ischemia (Banitt et al., 1996; Bijlstra et al., 1996a). The response 
could also be augmented by KATP channel activation suggesting that human forearm muscle 
contains a recruitable pool of KATP channels (Bank et al., 2000.; Bijlstra et al., 1996b). 
The standard practiceof sulphonlyurea treatment clinically has resulted in unintended 
consequences. Despite the effectiveness in combating hyperglycemia there appears to be an 
increased risk of cardiovascular mortality and morbidity with sulphonlyurea therapy (Fadini et 
al., 2015; Larsen et al., 1999; Morgan et al., 2014; Simpson et al., 2006). This may result from 
the effects of vascular KATP channel inhibition as described above. The extent of these issues has 
led the American College of Physicians to recommend that sulphonylureas be prescribed only in 
diabetes cases where diet, exercise and the hyperglycemia regulator metformin are not effective 
(Qaseem et al., 2012). 
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Chapter 2 - Acute blockade of ATP-sensitive K+ channels impairs 
skeletal muscle vascular control in rats during treadmill exercise 
 Abstract 
The ATP-sensitive K+ (KATP) channel is a class of inward rectifier K+ channels that can 
link local O2 availability to vasomotor tone across exercise-induced metabolic transients. This 
investigation tested the hypothesis that, if KATP channels are crucial to exercise hyperemia, 
inhibition via glibenclamide (GLI) would lower hindlimb skeletal muscle blood flow (BF) and 
vascular conductance (VC) during treadmill exercise. In 27 adult male Sprague Dawley rats 
mean arterial pressure (MAP), blood [lactate], and hindlimb muscle BF (radiolabelled 
microspheres) were determined at rest (n = 6) or during exercise (n = 6-8; 20, 40 and 60 m min-1, 
5% incline, i.e. ~60-100% maximal oxygen uptake) under control (CON) and GLI conditions (5 
mg kg-1, i.a). At rest and during exercise, MAP was higher (Rest: 17 ± 3, 20: 5 ± 1, 40: 5 ± 2, 60: 
5 ± 1 %, p < 0.05) with GLI. Hindlimb muscle BF (16 ± 7, 30 ± 9, 20 ± 8 %) and VC (20 ± 7, 33 
± 8, 24 ± 8 %) were lower with GLI during exercise at 20, 40 and 60 m min-1 respectively (p < 
0.05 for all), but not at rest. Within locomotory muscles there was a greater fractional reduction 
present in muscles comprised predominantly of type I and type IIa fibers at all exercise speeds (p 
< 0.05). Additionally, blood [lactate] was 106 ± 29 and 44 ± 15 % higher during exercise with 
GLI at 20 and 40 m min-1, respectively (p < 0.05). That KATP channel inhibition reduces 
hindlimb muscle BF during exercise in rats supports the obligatory contribution of KATP channels 
in large muscle mass exercise-induced hyperemia. 
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 Introduction 
The appropriate redistribution of cardiac output at exercise onset is achieved by vascular 
smooth muscle cell (SMC) relaxation in arterioles supplying active skeletal muscle and SMC 
contraction in arterioles supplying quiescent tissue. Within the active skeletal muscle vascular 
bed, local metabolic byproducts of muscle contraction (e.g. ATP, H+, K+, adenosine, etc.) as well 
as endothelium derived factors (e.g. NO, PGI2) are important for matching O2 supply with O2 
demand during exercise (Dinenno and Joyner, 2004; Hellsten et al., 2012; Symons et al. 1999) 
via modulation of vascular tone. The SMC resting membrane potential supports this balance by 
setting vascular tone as well as determining vasomotor sensitivity to depolarizing stimuli (i.e. 
sympathetic nerve activity; SNA). Modulation of membrane potential may therefore represent an 
important mechanism by which sympathetic vasoconstriction is attenuated in active skeletal 
muscle (Thomas et al. 1997).  
It is well recognized that the inward rectifier K+ channels (Kir) influence membrane 
potential and are capable of hyperpolarizing the SMC membrane resulting in an inhibitory effect 
on excitability and thus relaxation (Nelson and Quayle, 1995). Specifically, the vascular ATP-
sensitive K+ (KATP) channel is activated, in part, by the accumulation of subsarcolemmal ADP 
and may therefore contribute to the integration of local O2 availability with vasomotor control 
across the greater than 2 orders of magnitude increase in muscle metabolism seen with exercise. 
Importantly, KATP channel activation has been shown to result in SMC hyperpolarization, 
relaxation of vascular smooth muscle and attenuated α-adrenergic vasoconstriction (Mori et al., 
1995; Nakai and Ichihara, 1994; Quast et al., 1994; Tateishi and Faber, 1995). In healthy human 
forearm muscle the activation of KATP channels increases vasodilation in response to ischemia 
indicating the potential for KATP channels to contribute substantially to skeletal muscle O2 
8 
delivery during exercise (Bijlstra et al., 1996b). Despite early studies demonstrating that 
blockade of KATP channels significantly attenuates reactive and functional hyperemia in humans 
and animals (Bank et al., 2000; Banitt et al., 1996; Bijlstra et al. 1996a) more recent work has 
failed to confirm these results (Duncker et al., 2001; Farouque and Meredith, 2003; Schrage et 
al., 2006). As vasomotor control mechanisms may be fiber type dependent (e.g. Behnke et al., 
2011; Copp et al., 2010; Hirai et al., 1994) it is quite possible that, within muscles with specific-
fiber type composition, KATP channel activation may represent an obligatory mechanism 
supporting exercise-induced skeletal muscle hyperemia in vivo. Additionally, given that KATP 
channels are sensitive to metabolic status and that there exists considerable heterogeneity of 
metabolic characteristics among and within skeletal muscles it is plausible that KATP channel-
mediated vasodilation is dependent upon skeletal muscle fiber type distribution; a concept that 
cannot be addressed in humans with current technology. The differences in fiber type profile 
between species, muscles or states of dysfunction promotes remarkably different muscle O2 
tensions which may determine ADP accumulation and the open probability of KATP channels in 
the skeletal muscle vasculature. 
The purpose of the present investigation was to test the hypothesis that inhibition of KATP 
channels via glibenclamide (GLI) would reduce hindlimb skeletal muscle blood flow (BF) and 
vascular conductance (VC) and increase arterial blood [lactate] during submaximal treadmill 
exercise in healthy rats. Furthermore, given the purported coupling of cellular metabolism with 
vasomotor tone by KATP channels, it was anticipated that the reductions in VC with GLI would 
associate directly with the percentage of type I and type IIa fibers across muscles. 
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 Methods 
 Ethical approval 
All procedures were approved by the Institutional Animal Care and Use Committee of 
Kansas State University under the guidelines established by the National Institutes of Health and 
conducted according to the animal use guidelines mandated by The Journal of Physiology 
(Drummond, 2009). 27 adult male Sprague-Dawley rats (~4 months old, body mass = 366 ± 7 g) 
were maintained in accredited animal facilities (Association for the Assessment and 
Accreditation of Laboratory Animal Care) at Kansas State University on a 12-h light/12-h dark 
cycle with food and water provided ad libitum. Rats were separated into either rest (n = 6) or 3 
exercise (n = 6-8) groups and used for within-animal comparisons under control (CON) and KATP 
channel inhibition (GLI) conditions. Rats were acclimatized to running during a familiarization 
period comprised of 5-7 sessions on a custom-built motor-driven treadmill set at an incline of 
5%.  Each session consisted of running at progressive speeds from ~20 m min-1 to ~60 m min-1 
over a total duration of no more than 5 min. 
The pharmacological sulphonylurea derivative GLI (494 g mol-1; 5-chloro-N-(4-[N-
(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-2-methoxybenzamide; Sigma-Aldrich, St Louis, 
MO, USA) was used to achieve inhibition of vascular KATP channels. Briefly, 50 mg of GLI was 
dissolved in 4 ml of NaOH (0.1 M) under continuous sonication to produce a 12.5 mg ml-1 stock 
solution. A 5 mg kg-1 dose was drawn from the stock solution and diluted to ~1 ml with 
heparinized saline. Thomas et al. demonstrated that 20 mg/kg i.v. of glibenclamide reverses the 
effect of the same dose of diazoxide (Thomas et al., 1997). However, it has been reported 
previously that GLI is a selective KATP channel blocker at concentrations below 5 µmol L-1 
(Beech et al., 1993; Sadraei and Beech, 1995). The current dose of 5 mg kg-1 for rats of a mean 
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body mass of 366 g equates to a blood concentration of ~140 µmol L-1. Given that 98-99% of 
GLI is bound to plasma protein, the effective blood concentration of GLI is ~2-3 µmol L-1 
(George et al., 1990) which is in the range for GLI to be selective for KATP channels without 
possible inhibition of Ca+ channel current (Sadraei and Beech, 1995). This dosing strategy, based 
on smooth muscle cell investigations was shown to elicit a degree of KATP channel blockade for 
swine in vivo (60-70%; Duncker et al., 2001). 
 Surgical instrumentation 
On the day of the final protocol the rats were anesthetized initially with a 5% isoflurane-
O2 mixture and maintained on a 3% isoflurane-O2 mixture for the duration of the surgical 
instrumentation. Cannulation of both the carotid and caudal arteries was performed with PE-10 
connected to PE-50 (Intra-Medic polyethylene tubing, BD, Franklin Lakes, NJ, USA). The 
catheters were then tunneled subcutaneously to the dorsal aspect of the cervical region where 
they were exteriorized through a puncture wound in the skin. Following closure of incisions the 
rat was removed from anesthesia and given a minimum recovery period of 2 h. 
 Experimental protocol 
After the recovery period the exercise BF protocol was performed with the treadmill set 
at an incline of 5%. The rat was placed on the treadmill and the carotid catheter was attached to a 
pressure transducer (P23ID, Gould Statham Instruments, Hato Rey, Puerto Rico, USA) for the 
measurement of mean arterial pressure (MAP) and heart rate (HR) while the caudal catheter was 
connected to a 1-ml syringe attached to a Harvard pump (model 907, Holliston, MA, USA). 
Exercise (i.e. ~60-100% maximal oxygen uptake, "O2max) was initiated at a speed of 20 (n = 8), 
40 (n = 6) or 60 m min-1 (n = 7) and remained steady for ~3 min at which time pre-microspheres 
HR and pressures were recorded. At ~3.5 min of total exercise time blood withdrawal was 
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initiated from the caudal catheter at a rate of 0.25 ml min-1. The carotid catheter was then 
disconnected from the pressure transducer and ~0.5-0.6 106, 15 µm diameter microspheres (57Co 
or 85Sr in random order, Perkin Elmer Life and Analytical Sciences, Waltham, MA, USA) were 
rapidly infused into the aortic arch of the running animal for the determination of tissue BF. 
Upon reconnection of the carotid catheter to the pressure transducer a second pressure reading 
was immediately recorded post-microspheres. An arterial blood sample (0.2 ml) was then drawn 
from the carotid artery catheter for the determination of blood gases, hematocrit, pH, [lactate] 
and [glucose]. Exercise was terminated and the rat was continuously monitored during a 
minimum 30 min rest period before the second bout began. 
A post-recovery pressure was recorded to establish resting pressure and HR values. The 
KATP channel inhibitor GLI (5 mg kg-1) was infused via the caudal artery catheter. Pressure was 
monitored continuously until GLI elicited a persistent rise in MAP at which time the second 
exercise bout was initiated. The second bout and administration of microspheres were performed 
identically to the protocol described above. As demonstrated previously, subsequent control 
bouts of exercise for this protocol demonstrate high reproducibility of hemodynamic variables 
(MAP, HR, BF and VC; Sadraei and Beech, 1995). Upon exercise termination the rat was 
euthanized with an overdose of pentobarbital (>50 mg kg-1 body mass) via the carotid artery 
catheter. For another group of rats (n = 6) administration of microspheres, blood sampling and 
pressure recordings were performed at rest under CON and GLI conditions as described above.  
 Determination of BF and VC 
Correct placement of the carotid catheter in the aortic arch was verified by anatomical 
dissection. Hindlimb muscles and muscle portions as well as the lungs, kidneys, and 
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representative organs of the splanchnic region were removed, weighed and placed in counting 
vials for the determination of radioactivity.   
Radioactivity was measured for each tissue as well as the reference sample using a 
gamma scintillation counter (model 5230, Packard Auto Gamma Spectrometer, Downers Grove, 
IL, USA). Taking into account the cross-talk fraction between isotopes enabled radioactivity to 
be determined for separate microsphere injections (57Co or 85Sr). Based on this radioactivity BF 
to each tissue was determined for the individual conditions, CON or GLI, by comparison to the 
reference sample of known flow rate and measured radioactivity (Ishise et al., 1980; Musch and 
Terrell, 1992). Tissue BFs were expressed as ml min-1 (100 g)-1 of tissue and the results were also 
normalized to MAP and expressed as VC (ml min-1 (100 g)-1 mmHg-1). Adequate mixing of the 
microspheres for each BF determination was verified by a <15% difference in BF between the 
right and left kidneys or right and left hindlimbs. 
 Statistical analysis 
All variables were compared between and within groups using mixed two-way 
ANOVA’s and Student-Newman-Keuls post hoc tests where appropriate. Muscle fiber type 
composition was based on the percentage of type I, type IIa, type IIb, and type IId/x fibers in the 
individual muscles and muscle parts of the rat hindlimb as reported by Delp and Duan (1996). 
Pearson Product Correlations were used to test the relationship between changes in VC and 
muscle fiber type. Significance was set at p < 0.05 and values are expressed as mean ± SEM. 
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 Results 
There was no significant difference in body mass between groups (Rest: 365 ± 5, 20: 367 
± 13, 40: 407 ± 26, 60: 375 ± 15 g, p > 0.05).  
 Effects of GLI on HR, MAP, arterial blood gases, pH, hematocrit, [lactate] and 
[glucose] 
At rest and during exercise at all speeds MAP was higher with GLI compared to CON 
(Fig. 1). HR was lower with GLI only at rest and during exercise at 20 m min-1. Administration 
of the vehicle did not change MAP (Pre-vehicle: 127 ± 4, Post-vehicle: 125 ± 4 mmHg, p > 0.05) 
or HR (Pre-vehicle: 400 ± 18, Post-vehicle: 436 ± 19 mmHg, p > 0.05) in a subset of rats (n = 6). 
Arterial PO2 was higher with GLI at rest (CON: 96.8 ± 2.2 GLI: 107.7 ± 2.6 mmHg, p < 0.05) 
but not during exercise at any speed (p > 0.05 for all). Hematocrit was higher with GLI during 
exercise at 20 m min-1 only (CON: 31 ± 1, GLI: 33 ± 1 %, p < 0.05) while pH was lower with 
GLI during exercise at 40 m min-1 only (CON: 7.39 ± 0.02, GLI: 7.35 ± 0.03, p < 0.05). During 
exercise at both 40 (CON: 102 ± 6, GLI: 89 ± 8 mg dL-1) and 60 m min-1 (CON: 87 ± 4, GLI: 75 
± 3 mg dL-1) blood [glucose] was lower with GLI (p < 0.05 for both). Blood [lactate] was higher 
with GLI during exercise at 20 (CON: 2.0 ± 0.3, GLI: 4.1 ± 0.9 mmol L-1, p < 0.05) and 40 m 
min-1 (CON: 5.9 ± 0.5, GLI: 8.7 ± 1.4 mmol L-1, p < 0.05) but not at rest or 60 m min-1 (p > 0.05 
for both). 
 Effects of GLI on skeletal muscle BF and VC 
At rest there were no differences between groups in total hindlimb skeletal muscle BF or 
VC (Fig. 2, p = 0.40) or BF and VC to any of the individual muscles or muscle portions (Table 
1). During exercise at all speeds both total hindlimb skeletal muscle BF and VC were lower with 
GLI compared to CON (Fig. 2). Specifically, GLI resulted in a lower BF in 13, 20, and 14 of the 
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28 individual hindlimb muscles or muscle portions during exercise at 20, 40 and 60 m min-1, 
respectively (Table 2). VC was lower with GLI in 15, 21, and 18 of the 28 individual hindlimb 
muscles or muscle portions during exercise at 20, 40 and 60 m min-1, respectively (Table 3). 
Furthermore, there was a significant positive correlation between the percentage of type I and 
type IIa fibers and the percent decrease in VC for the 28 muscles or muscle portions of the 
hindlimb during exercise at 20 (r = -0.53), 40 (r = -0.69) and 60 m min-1 (r = -0.50). 
 Effects of GLI on renal and splanchnic BF and VC at rest and during exercise 
Renal BF and VC were reduced by GLI at rest but not during exercise at any speed 
(Table 3). Among the representative organs of the splanchnic region BF was reduced at rest to 
the spleen, adrenals and large intestine with GLI. VC was reduced at rest to the stomach, 
adrenals, spleen, pancreas, small intestine and large intestine with GLI. BF during exercise at 20 
m min-1 was reduced with GLI to the pancreas and small intestine, and VC was reduced to the 
stomach, pancreas and small intestine (Table 3). There was no difference in BF or VC between 
CON and GLI for any organs at 40 or 60 m min-1. However, at 40 and 60 m min-1 the CON renal, 
adrenal, pancreas and small intestine BF’s were lower compared to 20 m min-1. Similarly, renal, 
stomach, pancreas and large intestine VC’s were lower at both 40 and 60 compared to 20 m min-
1. 
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 Discussion 
The primary original findings of this investigation were that the inhibition of KATP 
channels in the rat via GLI during exercise increased MAP and decreased HR, reduced hindlimb 
skeletal muscle BF and VC and increased blood [lactate]. Furthermore, the decrease in VC with 
GLI reflected a fiber type-selective effect such that VC was reduced primarily to the muscles 
comprised of type I and type IIa fibers. The strength of the fiber type relationship persisted at 
higher speeds where muscle recruitment increasingly represents the complete spectrum of fiber 
types. These data support that KATP channels contribute significantly to exercise-induced skeletal 
muscle hyperemia during treadmill exercise in rats. 
The finding that GLI increased MAP at rest with a consequent decrease in HR is not 
surprising as this is consistent with previous reports at rest in conscious rats (Gardiner et al., 
1996; Moreau et al., 1994), swine (Duncker et al., 2001) and humans (Farouque and Meredith, 
2003). Specifically, the higher MAP and lower HR at rest with KATP channel inhibition were 
coincident with large reductions in renal and splanchnic VC and suggest the occurrence of KATP 
channel inhibition. This is in agreement with studies demonstrating a significant contribution of 
KATP channels to basal vasomotor tone in the systemic circulation of conscious rats (Gardiner et 
al., 1996, Moreau et al., 1994; Parekh and Zou, 1996), hamsters (Jackson, 1993; Saito et al., 
1996) and dogs (Comtois et al., 1994; Vanelli and Hussain, 1994). 
The similar hindlimb skeletal muscle BF and VC at rest with GLI is most likely due to 
the inhibition of KATP channels at physiological ATP concentrations or a compensatory 
vasodilation by redundant pathways (e.g. NO, PGI2, baroreflex) to maintain appropriate basal 
vasomotor tone (Hellsten et al., 2012). Similar observations have been made across species 
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(Duncker et al, 2001; Farouque and Meredith, 2003) although there is some evidence for modest 
skeletal muscle vascular KATP channel activity at rest (Nielsen et al., 2003). 
Previously, KATP channel blockade in rats and hamsters has been shown to reduce the 
skeletal muscle hyperemic response to electrically-induced contractions (Saito et al, 1996; 
Thomas et al., 1997). In this regard, our findings indicate that, in rats, KATP channel inhibition 
also reduces the in vivo skeletal muscle hyperemic response to treadmill running. This 
corroborates the notion that KATP channels represent an important mechanistic link between 
metabolism and vasomotor tone during exercise. The 20% decrease in hindlimb skeletal muscle 
VC during exercise at 20 m min-1 with GLI suggests that the rat locomotor muscle vascular bed 
contains a substantial pool of KATP channels which are activated even at moderate exercise 
intensities. Importantly, the 16% decrease in exercising hindlimb skeletal muscle BF occurred 
simultaneous with a doubling of arterial blood [lactate] (2.0 to 4.1 mmol L-1) with GLI at 20 and 
a 44% increase at 40 m min-1; an effect not seen at rest. Thus, not only is vasodilation attenuated 
in the hindlimb vasculature, but this decrement represents an impaired vasomotor control failing 
to meet the BF demands of the active skeletal muscle. These intriguing findings support the 
hypothesis that KATP channels are obligatory for exercise-induced hyperemia with respect to 
exercise tolerance and work capacity; at least within the rat. Furthermore, the magnitude of the 
KATP channel role may actually be underestimated herein. We acknowledge that incomplete KATP 
channel blockade may be present given that the precise degree of inhibition was not established. 
Consequently, the data herein may reflect only a portion of the KATP channel contribution to 
exercise-induced hyperemia. Regardless, the results demonstrate clearly the significant effects of 
GLI on skeletal muscle BF, VC and arterial blood [lactate]. The substantial increase of arterial 
blood [lactate] at 20 and 40 m min-1 is not surprising given that GLI-induced decreases in BF 
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were correlated with the percent type I and IIa fibers such that the predominantly oxidative 
muscles and muscle portions experienced the most consistent decrease in BF during exercise. 
The muscle fiber type composition explains ~28, 48 and 25% of the VC decrease with GLI at 20, 
40 and 60 m min-1, respectively. The preferential recruitment of type I and type IIa fibers during 
the low speed exercise protocol (~55-65% VO2max) is likely to account for a substantial portion of 
the fiber type-selective effect at 20 m min-1. However, the relationship persisted even at 40 and 
60 m min-1 when a greater proportion of type IIb/dx fibers were recruited. NO, which has a 
proportionally greater role in the control of oxidative fiber type vascular beds (Hirai et al., 1994), 
has been shown to operate through the activation of KATP channels (Murphy and Brayden, 1995; 
Tare et al., 1990). Thus, inhibition of KATP channels in the vasculature supplying type I and IIa 
fibers would result in a greater decrement of VC during exercise as it may block a portion of this 
NO-mediated vasodilation. Investigating the sensitivity of the fiber type relationship to work 
rates above and below fundamental physiological tipping points such as critical speed/power, 
lactate threshold, etc. may prove insightful. 
With respect to the interpretation of the effects of GLI on altered BF and VC as purely 
local muscle effects, the possible impacts of KATP channel inhibition on sympathetic nerve 
discharge must be considered. The loss of KATP channel-mediated hyperpolarization could 
conceivably result in increased sympathetic nerve discharge for a given stimulus which would 
account, in part, for the decrements in BF and VC seen herein. However, we consider this 
unlikely because it has been demonstrated, in male Sprague Dawley rats, that direct injection of 
GLI into the rostral ventrolateral medulla has no effect on blood pressure, HR or renal SNA 
(Guo et al., 2011). These findings support that GLI did not directly impact sympathetic nerve 
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discharge in the current study and that the reductions in BF and VC are the result, specifically, of 
muscle vascular KATP channel inhibition. 
It is important to note that the BF and VC results seen herein run contrary to data from 
exercising swine (Duncker et al., 2001). This may be the result of cross-species differences in 
vascular KATP channel expression and/or function. Indeed, while the octameric structure of 
vascular KATP channels is presumed to be the Kir6.1 pore-forming units with associated SUR2B 
subunits, considerable heterogeneity of functional expression has been demonstrated through 
readily occurring heteromultimerization of the pore forming units (Kir6.x) as well as the 
sulphonylurea receptor subunits (SURx) which confer the channel’s ATP sensitivity. 
Accordingly, there is substantial variation in unitary conductance which may impact the relative 
importance of the KATP channel in vasomotor control across species, tissue beds, and metabolic 
rates (rev. by Teramoto, 2006). This is particularly true for vascular KATP channels as the range 
of unitary conductance appears to be much greater (~20 to >200 pS) than for pancreatic β cells 
(~50 to 90 pS) and some regions of the heart and brain (~40 to 80 pS) (Cole and Clément-
Chomienne, 2003). Further exploration of the discrepancies in channel molecular structure 
across tissues may lead to better understanding of the functional consequences resulting from 
global KATP channel blockade. 
The role of KATP channels in the control of human skeletal muscle BF has been elucidated 
primarily by the use of KATP channel agonists, namely nicorandil and diazoxide, as well as the 
KATP channel inhibitor GLI. Seminal results include KATP channel agonists eliciting forearm 
vasodilation (Bijlstra et al., 1996a) and KATP channel blockade reducing the BF response to both 
reactive and functional hyperemia in some (Bank et al., 2000; Banitt et al., 1996; Bijlstra et al., 
1996b) but not all studies (Duncker et al., 2001, Schrage et al., 2006). The reason for the 
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differential conclusions drawn from use of KATP channel agonists versus blockers is unclear. In 
healthy humans, KATP channels may not be obligatory for achieving adequate skeletal muscle BF 
during exercise given the great redundancy of vasodilatory mediators (Hellsten et al., 2012). The 
potential for parallel pathways such as NO- and PGI2-mediated vasodilation to adequately meet 
BF requirements is present at relatively low workloads. This notion is consistent with KATP 
blockade studies in humans involving the forearm musculature which represents a small, non-
locomotory portion of the total body muscle mass. Furthermore, the putative variability of KATP 
channel expression among skeletal muscle vascular beds with vastly different metabolic 
characteristics may confound interpretation of the available human data. It appears that the 
vascular KATP channel subtype uniquely requires nucleotide diphosphates (i.e. ADP) for 
activation and thus is designated as a nucleotide-dependent K+ channel (KNDP; Beech et al., 
1993). As such, the channel would only demonstrate obligatory function where sufficiently low 
local muscle O2 tension results in pronounced vascular subsarcolemmal ADP accumulation. 
Under these conditions even a small impact of KATP channel activation on SMC membrane 
potential could drive large increases in vasodilation. This is due to the remarkably steep 
relationship between membrane potential and Ca2+ influx in smooth muscle; changes of only a 
couple of millivolts can reduce [Ca2+]i  ~30% (Nelson et al., 1990). For this reason, we are in 
agreement with Shrage et al (2006) who have recognized that the determination of KATP channel 
function across more diverse muscle vascular beds and a greater range of exercise 
intensities/paradigms is necessary to resolve the circumstances under which these channels 
impact O2 delivery. The in vivo measurements evaluating 28 muscles and muscle portions seen 
herein demonstrates the novel information to be gained from this approach. 
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The results seen herein suggest that the role of KATP channels may be potentiated under 
conditions of low local muscle O2 tension (i.e. when muscle fibers are recruited) which can 
increase vascular glycolytic flux and drive greater intracellular ADP accumulation. This 
environment is exacerbated in muscle fibers exposed to high metabolic demand as well as 
conditions characterized by skeletal muscle hypoxia such as heart failure (rev. by Poole et al., 
2012) type II diabetes (Cunha et al., 2008; Padilla et al., 2007) and aging (Poole and Ferreira, 
2007). Therefore, the potential for KATP channels to contribute significantly to exercise-induced 
skeletal muscle hyperemia has important implications for characterizing the etiology of blood-
muscle O2 transport decrements in these conditions. 
 Experimental considerations 
A major strength of the current experimental design is that each animal acts as its own 
control for the effects of GLI thus increasing statistical power and reducing animal use. 
However, the limitation of only 2 available isotopes precludes BF controls for the vehicle being 
performed in the same animal. To minimize animal use per IUCAC mandate, the effect of the 
vehicle on MAP and HR was assessed in a subset of animals (n = 6) with no change evident after 
administration of the vehicle. Furthermore, a similar NaOH/saline vehicle was shown to have no 
impact on the vascular hemodynamic response to contractions in Sprague Dawley rats (Thomas 
et al., 1997). 
Since GLI is not selective for vascular smooth muscle KATP channels it might be argued 
that GLI-induced KATP channel inhibition in the coronary vasculature or cardiac myocytes could 
account for the reduced BF during exercise seen herein. Measurements of coronary BF and VC 
were not available in the present investigation. However, decrements in cardiac output would not 
be expected to support a decrease in BF for select muscles or muscle portions as seen herein. 
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Likewise, the increase in MAP with GLI would not be consistent with decrements in cardiac 
output. These observations suggest that GLI does not impact coronary BF such that decrements 
in cardiac function (and reduced cardiac output) underlie the decrease in hindlimb skeletal 
muscle BF during submaximal treadmill exercise found herein. Additionally, given that 
inhibition of endothelial KATP channels can be achieved via GLI, the effects of KATP channel 
inhibition on vascular control may be mediated via altered endothelial function rather than a 
direct action on SMCs (Malester et al., 2007). However, the conclusion that KATP channels 
contribute to skeletal muscle vascular control during large muscle mass exercise in rats is 
independent of the ability to partition endothelial influence from direct SMC effects.  
The existence of mitochondrial membrane KATP channels requires the consideration that 
altered muscle O2 consumption or extraction impacts skeletal muscle BF. The limited evidence 
available for whole body exercising "O2 indicates no change with GLI (Larsen et al., 1999). This 
might be expected given that mitochondrial KATP channel blockade does not appear to alter the 
O2 cost of exercise per se. Furthermore, if an increase in O2 consumption occurred during 
treadmill exercise with GLI the regulation of O2 supply-demand described previously would 
dictate an increase in hindlimb skeletal muscle BF with GLI rather than the decrease seen herein. 
While O2 extraction for a given "O2 can increase with KATP channel blockade in cardiac muscle 
during submaximal exercise (Duncker et al., 2001) this effect, as dictated by the Fick equation, 
serves to offset the GLI-induced reductions in BF. Crucially, the use of mitochondrial-selective 
KATP channel blockers verifies that the GLI-induced reduction of myocardial "O2 in the canine 
during exercise is the result of reduced myocardial BF rather than a primary mitochondrial 
respiration effect (Chen et al., 2001). Thus, changes in O2 extraction or consumption appear to be 
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driven by impaired vascular control rather than a direct result of mitochondrial KATP channel 
inhibition. 
 Conclusions 
Our principal novel findings show that inhibition of KATP channels via GLI (5 mg kg-1) 
attenuates hindlimb skeletal muscle BF and VC and elevates blood [lactate] during submaximal 
treadmill exercise. The effects of KATP channel inhibition were significant across the range of 
exercise speeds employed and demonstrated a fiber type-selectivity within muscles comprised of 
highly oxidative fibers. These results provide compelling evidence that KATP channel-induced 
hyperpolarization constitutes an important mechanism of vasomotor control in exercising 
skeletal muscle supporting that KATP channels represent an obligatory pathway for skeletal 
muscle vascular control during large muscle mass exercise in healthy rats. 
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Table 2-1. Effects of GLI on individual hindlimb skeletal muscle BFs (ml min-1 (100 g)-1) 
and VCs (ml min-1 (100 g)-1 mmHg-1) for the rest group 
	 BF	 	 VC	
	 CON	 GLI	 	 CON	 GLI	
Ankle	extensors	 	 	 	 	 	
Soleus	(91%)	 115	±	20	 91	±	28	 	 0.88	±	0.15	 0.62	±	0.21	
Plantaris	(20%)	 18	±	4	 16	±	4	 	 0.14	±	0.03	 0.11	±	0.03	
Gastrocnemius,	red	(86%)	 57	±	18	 46	±	22	 	 0.44	±	0.15	 0.30	±	0.14	
Gastrocnemius,	white	(0%)	 11	±	3	 16	±	5	 	 0.09	±	0.03	 0.10	±	0.03	
Gastrocnemius,	mixed	(9%)	 20	±	5	 20	±	9	 	 0.16	±	0.04	 0.13	±	0.06	
Tibialis	posterior	(27%)	 26	±	10	 11	±	4	 	 0.21	±	0.08	 0.07	±	0.02	
Flexor	digitorum	longus	(32%)	 57	±	31	 65	±	48	 	 0.41	±	0.21	 0.38	±	0.26	
Flexor	halicus	longus	(29%)	 16	±	4	 9	±	2	 	 0.12	±	0.03	 0.06	±	0.01	
	 	 	 	 	 	
Ankle	flexors	 	 	 	 	 	
Tibialis	anterior,	red	(37%)	 59	±	17	 33	±	12	 	 0.45	±	0.13	 0.20	±	0.06	
Tibialis	anterior,	white	(20%)	 24	±	8	 17	±	4	 	 0.19	±	0.06	 0.11	±	0.03	
Extensor	digitorum	longus	(24%)	 22	±	5	 20	±	5	 	 0.16	±	0.04	 0.13	±	0.03	
Peroneals	(33%)	 27	±	7	 18	±	7	 	 0.22	±	0.06	 0.12	±	0.04	
	 	 	 	 	 	
Knee	extensors	 	 	 	 	 	
Vastus	intermedius	(96%)	 134	±	34	 101	±	44	 	 1.04	±	0.28	 0.70	±	0.30	
Vastus	medialis	(18%)	 38	±	14	 30	±	12	 	 0.30	±	0.12	 0.20	±	0.08	
Vastus	lateralis,	red	(65%)	 88	±	37	 87	±	45	 	 0.71	±	0.31	 0.59	±	0.29	
Vastus	lateralis,	white	(0%)	 10	±	2	 14	±	4	 	 0.08	±	0.01	 0.10	±	0.03	
Vastus	lateralis,	mixed	(11%)	 24	±	8	 24	±	8	 	 0.19	±	0.07	 0.16	±	0.05	
Rectus	femoris,	red	(34%)	 38	±	11	 28	±	13	 	 0.29	±	0.08	 0.18	±	0.09	
Rectus	femoris,	white	(0%)	 21	±	4	 16	±	5	 	 0.17	±	0.04	 0.11	±	0.03	
	 	 	 	 	 	
Knee	flexors	 	 	 	 	 	
Biceps	femoris	anterior	(0%)	 12	±	3	 12	±	2	 	 0.10	±	0.03	 0.08	±	0.02	
Biceps	femoris	posterior	(8%)	 20	±	7	 16	±	5	 	 0.16	±	0.05	 0.10	±	0.03	
Semitendinosus	(17%)	 23	±	7	 15	±	4	 	 0.19	±	0.06	 0.10	±	0.02	
Semimembranosus,	red	(28%)	 25	±	12	 17	±	4	 	 0.20	±	0.09	 0.12	±	0.03	
Semimembranosus,	white	(0%)	 13	±	2	 10	±	1	 	 0.10	±	0.02	 0.07	±	0.01	
	 	 	 	 	 	
Thigh	adductors	 	 	 	 	 	
Adductor	longus	(95%)	 97	±	14	 74	±	20	 	 0.76	±	0.11	 0.50	±	0.15	
Adductor	magnus	&	brevis	(11%)	 31	±	14	 22	±	7	 	 0.25	±	0.11	 0.15	±	0.05	
Gracilis	(23%)	 23	±	9	 14	±	3	 	 0.18	±	0.07	 0.09	±	0.02	
Pectineus	(31%)	 29	±	10	 20	±	6	 	 0.23	±	0.08	 0.13	±	0.04	
	 	 	 	 	 	
Data are mean ± SEM. Values in parentheses indicate % type I + IIa according to Delp & Duan (1996). Rest; n = 6, 
Exercise; n = 8. *P < 0.05 versus control. 
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Table 2-2. Effects of GLI on individual hindlimb skeletal muscle BFs for exercise groups 
	 20	 	 40	 	 60	
	 CON	 GLI	 	 CON	 GLI	 	 CON	 GLI	
Ankle	extensors	 	 	 	 	 	 	 	 	
Soleus	(91%)	 382	±	19	 277	±	21*	 	 293	±	63	 152	±	25*†	 	 312	±	15	 213	±	28*	
Plantaris	(20%)	 253	±	25	 209	±	21	 	 254	±	35	 193	±	32*	 	 258	±	15	 223	±	10	
Gastrocnemius,	red	(86%)	 419	±	40	 337	±	33*	 	 395	±	70	 238	±	52*	 	 432	±	11	 351	±	41	
Gastrocnemius,	white	(0%)	 53	±	13	 69	±	9	 	 82	±	15	 81	±	11	 	 93	±	13	 85	±	11	
Gastrocnemius,	mixed	(9%)	 161	±	9	 152	±	16	 	 182	±	28	 137	±	21*	 	 201	±	9	 167	±	13*	
Tibialis	posterior	(27%)	 192	±	23	 161	±	16	 	 229	±	37	 162	±	20*	 	 285	±	22	 222	±	21*	
Flexor	digitorum	longus	(32%)	 118	±	17	 105	±	20	 	 116	±	8	 86	±	16	 	 122	±	11	 124	±	15	
Flexor	halicus	longus	(29%)	 107	±	14	 87	±	12*	 	 117	±	21	 84	±	15*	 	 107	±	12	 96	±	10	
	 	 	 	 	 	 	 	 	
Ankle	flexors	 	 	 	 	 	 	 	 	
Tibialis	anterior,	red	(37%)	 383	±	24	 337	±	39	 	 420	±	63	 270	±	40*	 	 405	±	23	 334	±	40	
Tibialis	anterior,	white	(20%)	 136	±	12	 139	±	18	 	 157	±	24	 93	±	17*	 	 127	±	14	 117	±	15	
Extensor	digitorum	longus	(24%)	 70	±	5	 72	±	5	 	 128	±	27†	 97	±	15	 	 94	±	9	 97	±	13	
Peroneals	(33%)	 169	±	13	 144	±	19	 	 172	±	22	 112	±	9*	 	 149	±	17	 122	±	10	
	 	 	 	 	 	 	 	 	
Knee	extensors	 	 	 	 	 	 	 	 	
Vastus	intermedius	(96%)	 419	±	25	 299	±	18*	 	 407	±	69	 262	±	40*	 	 456	±	16	 321	±	31*	
Vastus	medialis	(18%)	 249	±	15	 186	±	11*	 	 245	±	34	 169	±	27*	 	 277	±	15	 221	±	15*	
Vastus	lateralis,	red	(65%)	 464	±	27	 306	±	42*	 	 325	±	48†	 196	±	44*	 	 396	±	26	 291	±	36*	
Vastus	lateralis,	white	(0%)	 56	±	20†	 57	±	14	 	 68	±	12	 68	±	14	 	 99	±	7	 82	±	11	
Vastus	lateralis,	mixed	(11%)	 200	±	12†	 139	±	16*	 	 186	±	21	 123	±	25*	 	 236	±	20	 180	±	15*	
Rectus	femoris,	red	(34%)	 324	±	29	 233	±	25*	 	 280	±	33	 196	±	23*	 	 333	±	21	 263	±	26*	
Rectus	femoris,	white	(0%)	 146	±	15	 113	±	10*	 	 141	±	15	 113	±	18	 	 187	±	12‡	 146	±	13*	
	 	 	 	 	 	 	 	 	
Knee	flexors	 	 	 	 	 	 	 	 	
Biceps	femoris	anterior	(0%)	 34	±	4	 41	±	6	 	 72	±	16†	 62	±	10	 	 74	±	5	 63	±	7	
Biceps	femoris	posterior	(8%)	 106	±	11	 93	±	10	 	 119	±	15	 78	±	17*	 	 138	±	11	 103	±	15*	
Semitendinosus	(17%)	 77	±	7	 77	±	15	 	 73	±	9	 45	±	4*	 	 50	±	9	 50	±	8	
Semimembranosus,	red	(28%)	 137	±	19	 123	±	14	 	 173	±	16	 110	±	17*	 	 215	±	14	 170	±	20*‡	
Semimembranosus,	white	(0%)	 40	±	6	 47	±	7	 	 59	±	10	 41	±	8*	 	 91	±	15‡	 76	±	15*‡	
	 	 	 	 	 	 	 	 	
Thigh	adductors	 	 	 	 	 	 	 	 	
Adductor	longus	(95%)	 396	±	18	 251	±	32*	 	 254	±	50†	 111	±	12*†	 	 273	±	31	 164	±	22*	
Adductor	magnus	&	brevis	(11%)	 142	±	10	 99	±	6*	 	 118	±	6	 86	±	9*	 	 147	±	15	 118	±	13*	
Gracilis	(23%)	 81	±	13	 58	±	7*	 	 69	±	11	 57	±	12	 	 66	±	18	 55	±	11	
Pectineus	(31%)	 104	±	19	 58	±	8*	 	 112	±	19	 83	±	25	 	 77	±	14	 55	±	5	
	 	 	 	 	 	 	 	 	
Data are mean ± SEM. Values in parentheses indicate % type I + IIa according to Delp & Duan (1996). Rest; n = 6, 
Exercise; n = 8. *P < 0.05 versus control 
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Table 2-3. Effects of GLI on individual hindlimb skeletal muscle VCs for exercise groups 
	 20	 	 40	 	 60	
	 CON	 GLI	 	 CON	 GLI	 	 CON	 GLI	
Ankle	extensors	 	 	 	 	 	 	 	 	
Soleus	(91%)	 2.76	±	0.20	 1.92	±	0.20*	 	 2.04	±	0.48	 0.99	±	0.15*†	 	 2.21	±	0.11	 1.44	±	0.19*	
Plantaris	(20%)	 1.83	±	0.21	 1.45	±	0.18*	 	 1.75	±	0.26	 1.26	±	0.21*	 	 1.84	±	0.12	 1.50	±	0.07	
Gastrocnemius,	red	(86%)	 3.02	±	0.32	 2.33	±	0.27*	 	 2.75	±	0.56	 1.56	±	0.34*	 	 3.07	±	0.14	 2.38	±	0.30*	
Gastrocnemius,	white	(0%)	 0.37	±	0.08	 0.47	±	0.07	 	 0.56	±	0.11	 0.53	±	0.07	 	 0.67	±	0.11	 0.58	±	0.08	
Gastrocnemius,	mixed	(9%)	 1.15	±	0.06	 1.04	±	0.13	 	 1.26	±	0.22	 0.90	±	0.14*	 	 1.44	±	0.10	 1.14	±	0.10*	
Tibialis	posterior	(27%)	 1.36	±	0.14	 1.10	±	0.10	 	 1.57	±	0.25	 1.06	±	0.13*	 	 2.01	±	0.14‡	 1.50	±	0.14*	
Flexor	digitorum	longus	(32%)	 0.84	±	0.12	 	0.71	±	0.13	 	 0.80	±	0.07	 	0.56	±	0.10	 	 	0.88	±	0.10	 	0.83	±	0.09	
Flexor	halicus	longus	(29%)	 0.75	±	0.09	 0.59	±	0.09*	 	 0.80	±	0.14	 0.54	±	0.09*	 	 0.77	±	0.10	 0.65	±	0.07	
	 	 	 	 	 	 	 	 	
Ankle	flexors	 	 	 	 	 	 	 	 	
Tibialis	anterior,	red	(37%)	 2.76	±	0.20	 2.32	±	0.28	 	 2.92	±	0.50	 1.77	±	0.26*	 	 2.88	±	0.17	 2.24	±	0.27*	
Tibialis	anterior,	white	(20%)	 0.98	±	0.09	 0.96	±	0.12	 	 1.10	±	0.19	 0.61	±	0.11*	 	 0.90	±	0.10	 0.79	±	0.10	
Extensor	digitorum	longus	(24%)	 0.50	±	0.04	 0.49	±	0.03	 	 0.87	±	0.17†	 0.63	±	0.09*	 	 0.67	±	0.08	 0.65	±	0.08	
Peroneals	(33%)	 1.22	±	0.10	 0.99	±	0.13*	 	 1.19	±	0.17	 0.73	±	0.06*	 	 1.06	±	0.12	 0.82	±	0.07*	
	 	 	 	 	 	 	 	 	
Knee	extensors	 	 	 	 	 	 	 	 	
Vastus	intermedius	(96%)	 3.00	±	0.18	 2.06	±	0.16*	 	 2.79	±	0.48	 1.69	±	0.24*	 	 3.24	±	0.15	 2.15	±	0.20*	
Vastus	medialis	(18%)	 1.79	±	0.13	 1.29	±	0.11*	 	 1.68	±	0.24	 1.10	±	0.17*	 	 1.97	±	0.14	 1.49	±	0.10*	
Vastus	lateralis,	red	(65%)	 3.34	±	0.24	 2.12	±	0.34*	 	 2.23	±	0.34†	 1.28	±	0.28*	 	 2.81	±	0.19	 1.95	±	0.23*	
Vastus	lateralis,	white	(0%)	 0.40	±	0.15	 0.40	±	0.10	 	 0.46	±	0.07	 0.44	±	0.09	 	 0.70	±	0.06	 0.56	±	0.07	
Vastus	lateralis,	mixed	(11%)	 1.44	±	0.11	 0.96	±	0.13*	 	 1.29	±	0.17	 0.81	±	0.16*	 	 1.67	±	0.14	 1.21	±	0.09*	
Rectus	femoris,	red	(34%)	 2.35	±	0.26	 1.62	±	0.21*	 	 1.92	±	0.23	 1.28	±	0.15*	 	 2.36	±	0.16	 1.77	±	0.17*	
Rectus	femoris,	white	(0%)	 1.05	±	0.13	 0.78	±	0.08*	 	 0.97	±	0.11	 0.74	±	0.12	 	 1.32	±	0.07‡	 0.98	±	0.08*	
	 	 	 	 	 	 	 	 	
Knee	flexors	 	 	 	 	 	 	 	 	
Biceps	femoris	anterior	(0%)	 0.24	±	0.03	 0.28	±	0.04	 	 0.49	±	0.11†	 0.40	±	0.06	 	 0.53	±	0.04	 0.43	±	0.05*	
Biceps	femoris	posterior	(8%)	 0.76	±	0.08	 0.64	±	0.07	 	 0.83	±	0.12	 0.51	±	0.11*	 	 0.98	±	0.09	 0.70	±	0.11*	
Semitendinosus	(17%)	 0.55	±	0.05	 0.52	±	0.10	 	 0.50	±	0.06	 0.30	±	0.03*†	 	 0.36	±	0.07	 0.34	±	0.06	
Semimembranosus,	red	(28%)	 0.98	±	0.14	 0.84	±	0.09	 	 1.20	±	0.13	 0.73	±	0.12*	 	 1.53	±	0.11	 1.15	±	0.14*‡	
Semimembranosus,	white	(0%)	 0.28	±	0.04	 0.32	±	0.04	 	 0.40	±	0.07	 0.28	±	0.06*	 	 0.65	±	0.12‡	 0.51	±	0.10*	
	 	 	 	 	 	 	 	 	
Thigh	adductors	 	 	 	 	 	 	 	 	
Adductor	longus	(95%)	 2.85	±	0.16	 1.74	±	0.25*	 	 1.77	±	0.39†	 0.72	±	0.07*†	 	 1.94	±	0.22	 1.11	±	0.15*	
Adductor	magnus	&	brevis	(11%)	 1.02	±	0.08	 0.68	±	0.05*	 	 0.81	±	0.06	 0.56	±	0.16*	 	 1.06	±	0.13	 0.80	±	0.09*	
Gracilis	(23%)	 0.58	±	0.09	 0.39	±	0.04*	 	 0.47	±	0.07	 0.37	±	0.08	 	 0.47	±	0.13	 0.37	±	0.08	
Pectineus	(31%)	 0.75	±	0.14	 0.40	±	0.05*	 	 0.76	±	0.12	 0.54	±	0.10	 	 0.56	±	0.12	 0.37	±	0.03	
	 	 	 	 	 	 	 	 	
Data are mean ± SEM. Values in parentheses indicate % type I + IIa according to Delp & Duan (1996). Rest; n = 6, 
Exercise; n = 8. *P < 0.05 versus control 
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Table 2-4. Effects of GLI on BF (ml min-1 (100 g)-1) and VC (ml min-1 (100 g)-1 mmHg-1) in the kidneys and organs of the 
splanchnic region for rest and exercise groups. 
 Rest  20  40  60 
 CON GLI  CON GLI  CON GLI  CON GLI 
BF            
Kidney 488 ± 50 380 ± 27*  455 ± 42 417 ± 47  237 ± 107#† 164 ± 49#†  217 ± 25#† 190 ± 26#† 
Stomach 100 ± 21 48 ± 8  101 ± 15 73 ± 27  86 ± 52 97 ± 72  35 ± 2 64 ± 43 
Adrenals 718 ± 144 405 ± 45*  448 ± 55# 419 ± 69  253 ± 53#† 262 ± 63  217 ± 24#† 242 ± 21 
Spleen 397 ± 82 307 ± 88*  113 ± 28# 115 ± 31#  27 ± 14# 21 ± 6#  25 ± 4# 16 ± 3# 
Pancreas 142 ± 26 108 ± 15  198 ± 31 92 ± 22*  80 ± 27† 40 ± 9†  65 ± 7#† 38 ± 7 
Sm. Intestine 304 ± 41 257 ± 37  304 ± 40 229 ± 40*  155 ± 41#† 107 ± 24#†  141 ± 8#† 88 ± 12#† 
Lg. Intestine 218 ± 48 98 ± 14*  153 ± 30 116 ± 28  107 ± 35# 72 ± 23  83 ± 9# 55 ± 13 
Liver** 31 ± 6 37 ± 9  20 ± 7 20 ± 6  21 ± 5 19 ± 5  26 ± 1 21 ± 3 
            
VC            
Kidney 3.82 ± 0.50 2.53 ± 0.24*  3.30 ± 0.36 2.88 ± 0.36  1.66 ± 0.75#† 1.08 ± 0.32#†  1.53 ± 0.16#† 1.28 ± 0.18#† 
Stomach 0.76 ± 0.15 0.32 ± 0.04*  0.64 ± 0.08 0.33 ± 0.05*  0.22 ± 0.06#† 0.15 ± 0.03  0.24 ± 0.01#† 0.14 ± 0.02 
Adrenals 5.73 ± 1.32 2.69 ± 0.33*  3.17 ± 0.35# 2.92 ± 0.55  1.75 ± 0.40# 1.70 ± 0.40  1.52 ± 0.14# 1.61 ± 0.10 
Spleen 3.08 ± 0.66 1.99 ± 0.54*  0.83 ± 0.23# 0.82 ± 0.24#  0.19 ± 0.10# 0.14 ± 0.04#  0.18 ± 0.03# 0.11 ± 0.02# 
Pancreas 1.13 ± 0.22 0.72 ± 0.12*  1.46 ± 0.26 0.65 ± 0.16*  0.56 ± 0.20#† 0.26 ± 0.06  0.46 ± 0.05#† 0.25 ± 0.05 
Sm. Intestine 2.35 ± 0.31 1.71 ± 0.27*  2.23 ± 0.35 1.62 ± 0.31*  1.08 ± 0.31# 0.71 ± 0.17  1.00 ± 0.05# 0.60 ± 0.09 
Lg. Intestine 1.72 ± 0.38 0.64 ± 0.07*  1.11 ± 0.25# 0.90 ± 0.21  0.79 ± 0.23#† 0.50 ± 0.14#†  0.58 ± 0.06#† 0.41 ± 0.08#† 
Liver** 0.24 ± 0.05 0.24 ± 0.06  0.14 ± 0.04 0.14 ± 0.04  0.14 ± 0.04 0.12 ± 0.03  0.18 ± 0.01 0.14 ± 0.02 
 
            
Data are mean ± SEM.  Rest; n = 6, Exercise; n = 8.*P < 0.05 versus control.  **Indicates arterial, not portal, BF and VC.
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Figure 2-1. GLI increased MAP (A) at rest and during submaximal exercise at 20, 40 and 
60 m min-1 while HR (B) was decreased at rest and 20 m min-1.  *, p < 0.05 versus control. 
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Figure 2-2. GLI decreased total hindlimb skeletal muscle BF (A) and VC (B) during 
submaximal exercise at 20, 40 and 60 m min-1 but not at rest compared to CON.  *, p < 0.05 
versus control. 
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Figure 2-3. The percent decreases in exercising hindlimb VC with GLI were positively 
correlated with the percent type I and type IIa fibers of the muscles or muscle portions for 
at speeds of 20 (A), 40 (B) and 60 (C) m min-1. p < 0.05 versus control. 
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Chapter 3 - Modulation of rat skeletal muscle microvascular O2 
pressure via KATP channel inhibition following the onset of 
contractions 
 Abstract 
Vascular hyperpolarization mediated, in part, by the ATP-sensitive K+ (KATP) channel 
contributes to exercise-induced increases in skeletal muscle O2 delivery. We hypothesized that 
KATP channel inhibition via glibenclamide (GLI) would speed the fall of microvascular O2 
driving pressure (PO2mv; set by the O2 delivery-O2 utilization ratio), during muscle contractions. 
Spinotrapezius muscle PO2mv (phosphorescence quenching) was measured in 12 adult Sprague 
Dawley rats during 180 s of 1-Hz twitch contractions (~6 V) under control and GLI (5 mg/kg) 
conditions. The total mean PO2mv response time was greater with GLI (i.e. slowed; control: 42.0 
± 14.2, GLI: 79.5 ± 14.7 s, p < 0.05). A clear undershoot of the contracting steady-state PO2mv 
was evident with GLI (15.6 ± 5.3 %, p < 0.05) but not control (2.3 ± 1.6 %, p > 0.05). This 
indicates that KATP channel inhibition does not speed PO2mv kinetics per se during small muscle 
mass contraction. However, it does induce a transient mismatch of O2 delivery-O2 utilization, 
lowers PO2mv, and delays attainment of the contracting steady-state. 
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 Introduction 
The transport of O2 from alveoli in the lung to skeletal muscle mitochondria involves 
pressure-driven delivery across multiple resistances in series. Vitally important among these 
gradients is the pressure head driving O2 from capillary blood to skeletal myocytes which is 
determined by the microvascular oxygen pressure (PO2mv) in accordance with Fick’s Law of 
diffusion. The PO2mv is set by the ratio of O2 delivery (QO2) to O2 utilization (VO2) and, at the 
onset of contractions, this pressure provides a fundamental characterization of temporal O2 
delivery as it attempts to match near-instantaneous increases in O2 demand (Behnke et al., 2002; 
Ferreira et al., 2005). Fortunately, in healthy individuals the mechanical, neural and humoral 
mechanisms of vascular control are capable of producing remarkably fast muscle O2 delivery 
kinetics to maintain an adequate PO2mv during the metabolic transients of daily activity (rev. 
Heinonen et al., 2015; Joyner and Casey, 2015). This function is essential given that even a brief 
mismatch of O2 delivery-to-utilization at the onset of exercise can cause a premature decline in 
muscle PCr stores and the accumulation of muscle metabolites associated with fatigue such as 
ADP, H+, K+ and Pi (Hogan et al., 1992; Richardson et al., 1995; Wilson et al., 1977). 
Vasomotor sensitivity to depolarization depends upon the membrane potential of vascular 
smooth muscle cells and thus the modulation of membrane potential may represent an important 
mechanism contributing to the kinetics of vascular control and skeletal muscle O2 delivery 
during exercise. The vascular ATP-sensitive K+ (KATP) channel subtype is a nucleotide-
dependent, inward rectifier K+ channel (Kir) that is activated, in part, by the accumulation of 
subsarcolemmal ADP (Beech et al., 1993). The KATP channel may therefore help coordinate local 
O2 availability and vasomotor tone across the greater-than-two orders of magnitude increase in 
muscle metabolism seen with exercise. KATP channel activation elicits the smooth muscle 
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hyperpolarization characteristic of Kir channels, resulting in the relaxation of smooth muscle and 
attenuated α-adrenergic vasoconstriction (Keller et al., 2004; Nakai and Ichihara, 1994; Tateishi 
and Faber, 1995). The ability to couple vascular tone with cellular metabolism makes the KATP 
channel a strong candidate for contributing to the increased O2 delivery at the onset of 
contractions. In vivo investigations of KATP channel function are equivocal; some demonstrating 
robust effects on the magnitude of the hyperemic response at steady-state (Banitt et al., 1996; 
Bank et al., 2000; Bijlstra et al., 1996; Holdsworth et al., 2015) while others find no change 
(Duncker et al., 2001; Farouque and Meredith, 2003; Schrage et al., 2006). These disparate 
findings may belie an important KATP channel contribution to the speed, rather than magnitude, 
of the hyperemic response under specific circumstances (i.e. muscle mass, oxidative capacity, 
exercise intensity, etc.). Indeed, because of the redundancy of vasodilatory mediators the 
eventual attainment of steady-state PO2mv might be anticipated irrespective of the participation 
of KATP channels, or not, in the exercise hyperemia (Clifford and Hellsten, 2004).  
The tight regulation of O2 delivery to O2 utilization across the metabolic transition has 
historically been credited as a dominant feature of the exercise response (Krogh and Lindhard, 
1913; rev. Poole and Jones, 2012). Hence careful examination of the contraction-induced muscle 
PO2mv kinetics prior to the attainment of a steady-state is obligatory to understanding the role(s) 
of vascular KATP channel function in vivo. The purpose of the present investigation was to test 
the hypothesis that inhibition of KATP channels via glibenclamide (GLI) in healthy rats would 1) 
accelerate the fall of PO2mv following the onset spinotrapezius muscle contractions and 2) result 
in a lower mean PO2mv during the total duration of contractions. 
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 Methods 
 Ethical approval 
All procedures were approved by the Institutional Animal Care and Use Committee of 
Kansas State University under the guidelines established by the National Institutes of Health. 12 
adult male Sprague-Dawley rats (~4 months old) were maintained in accredited animal facilities 
(Association for the Assessment and Accreditation of Laboratory Animal Care) at Kansas State 
University on a 12-h light/12-h dark cycle with food and water provided ad libitum. 
 Drugs 
The pharmacological sulphonylurea derivative GLI (494 g mol-1; 5-chloro-N-(4-[N-
(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-2-methoxybenzamide; Sigma-Aldrich, St Louis, 
MO, USA) was used to inhibit vascular KATP channels. Briefly, 25 mg of GLI was dissolved in 
99:1 ratio of saline/NaOH (1.0 M) to produce a 2.5 mg ml-1 stock solution. A 5 mg kg-1 dose was 
drawn from the stock solution and diluted to ~1 ml with heparinized saline. It has been reported 
previously that GLI is a selective KATP channel blocker at concentrations below 5 µmol L-1 
(Beech et al., 1993; Sadraei and Beech, 1995). The current dose of 5 mg kg-1 for rats of a mean 
body mass of 366 g equates to a blood concentration of ~140 µmol L-1. Given that 98-99% of 
GLI is bound to plasma protein, the effective blood concentration of GLI is ~2-3 µmol L-1 
(George et al., 1990) which is in the range for GLI to be selective for KATP channels without 
inhibition of Ca2+ channel current (Sadraei and Beech, 1995). This dosing strategy, based on 
smooth muscle cell investigations, was shown to elicit a degree of KATP channel block for swine 
in vivo (Duncker et al., 2001). See Discussion for further considerations of KATP channel 
inhibition. 
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 Surgical instrumentation 
On the day of the final protocol the rats were anesthetized initially with a 5% isoflurane-
O2 mixture and maintained on a 3% isoflurane-O2 mixture for the duration of the surgical 
instrumentation. The carotid artery was cannulated with PE-10 connected to PE-50 (Intra-Medic 
polyethylene tubing, BD, Franklin Lakes, NJ, USA) for the measurement of mean arterial 
pressure (MAP) and heart rate (HR) as well as infusion of the phosphorescent probe G2. A 
caudal artery catheter was placed for blood sampling and administration of anesthetics. 
Isoflurane-O2 inhalation was progressively removed as anesthesia was maintained with 
pentobarbital sodium administered via the caudal artery catheter to effect. Depth of anesthesia 
was monitored at frequent and regular intervals via the blink and toe-pinch reflexes as well as 
magnitude and frequency of ventilation. Access to the spinotrapezius was achieved by surgically 
reflecting the overlying skin and fascia. The spinotrapezius muscle was selected because the 
fiber-type composition and oxidative capacity closely resembles that of the human quadriceps 
muscle group which makes it a useful analog of human locomotor muscle (Delp and Duan, 
1996). During both the surgical preparation and experimental protocol the muscle was 
superfused frequently with Krebs-Hensleit bicarbonate-buffered solution consisting of (in mM) 
4.7 KCl, 2.0 CaCl2, 2.4 MgSO4, 131 NaCl, and 22 NaHCO3 equilibrated with 5% CO2 and 95% 
N2 (pH 7.4, 37-38°C). Exposed tissue surrounding the spinotrapezius muscle was covered with 
Saran wrap (Dow Brands, Indianapolis, IN) to reduce dehydration and limit exposure of GLI to 
the spinotrapezius only. Stainless steel electrodes were sutured to the rostral (cathode) and caudal 
(anode) regions of the spinotrapezius muscle for electrically-induced twitch contractions. As 
previously reported by our laboratory these surgical procedures do not impact the microvascular 
integrity and responsiveness of the rat spinotrapezius muscle (Bailey et al., 2000). 
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 Experimental protocol 
Two separate contraction bouts were performed under control (saline/NaOH vehicle, i.a.) 
and GLI (5 mg/kg, i.a.) conditions. The vehicle (~1 ml) was administered for control via the 
caudal artery catheter followed by a 180 s muscle PO2mv recording. After a 1-3 minute period to 
ensure that baseline PO2mv had stabilized, muscle contraction was evoked via electrical 
stimulation (1 Hz, ~6 V, 2-ms pulse duration, model s48; Grass Technologies, Quincy, MA) for 
180 s. This protocol has been shown to increase blood flow four- to five-fold and metabolic rate 
six- to seven-fold without altering blood pH and is consistent with moderate intensity exercise 
(Behnke et al., 2002; Hirai et al., 2013). Immediately upon cessation of electrical stimulation an 
arterial blood sample was drawn (~0.8 ml) for the determination of blood gases, hematocrit, pH, 
[lactate] and [glucose]. After a ~25 min recovery the second contraction bout was performed in 
an identical fashion to the first after the administration of GLI (5 mg/kg). As previously reported 
by our laboratory, >20 min recovery elicits reproducible PO2mv responses (Copp et al., 2009; 
Herspring et al., 2008). At the end of the protocol, rats were euthanized with intra-arterial 
pentobarbital sodium overdose (>50 mg/kg) and subsequent removal of the heart. 
 Spinotrapezius PO2mv measurement 
PO2mv was measured via phosphorescence quenching using a frequency domain 
phosphorometer (PMOD 5000; Oxygen Enterprises, Philadelphia, PA). As described previously 
(Behnke et al., 2001), this technique applies the Stern-Volmer relationship (Rumsey et al., 1988), 
which describes the quantitative O2 dependence of the phosphorescent probe G2 via the 
equation: 
PO2mv = [(τ°/ τ) – 1]/(kQ · τ°) 
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where kQ is the quenching constant and τ and τ° are the phosphorescence lifetimes at the ambient 
O2 concentration and in the absence of O2, respectively. For the phosphorescent probe G2, kQ is 
273 mmHg-1 s-1 and τ° is 251 µs (Bodmer et al., 2012; Dunphy et al., 2002). These 
characteristics do not change over the physiological range of pH (~7.4) and temperature (~38°C) 
in vivo and, therefore, the phosphorescence lifetime is affected solely by the O2 partial pressure. 
The Pd-porphyrin cores of phosphor probes bind to albumin; the primary macromolecule in 
plasma. This quality as well as the probes’ negative charge ensures restriction to the vascular 
compartment, of which, the capillary bed volumetrically constitutes the major intramuscular 
space (Poole et al., 2004). After infusion of G2 the common end of the bifurcated light guide 
with a >500 µm penetration depth was positioned ~2-4 mm superficial to the dorsal surface of 
the exposed spinotrapezius muscle in an area devoid of macro-vessels. The phosphorometer 
modulates sinusoidal excitation frequencies between 100 Hz and 20 kHz and allows 
phosphorescence lifetime measurements from 10 µs to ~2.5 ms. PO2mv was measured 
continuously and recorded at 2-s intervals throughout the duration of the experimental protocol. 
 Analysis of spinotrapezius PO2mv kinetics 
PO2mv time course was determined via exponential regression analysis by applying the 
Levenberg-Marquardt algorithm (SigmaPlot 11.0; Systat software, San Jose, CA) to the 
contraction-induced PO2mv transient. The sum of squared residuals was used to indicate the 
appropriateness of the model fit. PO2mv responses were fit with either a one- or two-component 
model as follows. 
One component: 
PO2mv(t) = PO2mv(BL) – ΔPO2mv (1 – e - (t - TD) / τ) 
Two component: 
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PO2mv(t) = PO2mv(BL) – Δ1PO2mv (1 – e - (t – TD1) / τ1) + Δ2PO2mv (1 – e - (t – TD2) / τ2) 
PO2mv(t) is the PO2mv at a given time t; PO2mv(BL) corresponds to the pre-contracting 
resting PO2mv; Δ1 and Δ2 are the amplitudes for the first and second components, respectively; 
TD1 and TD2 are the independent time delays for each component; and τ1 and τ2 are the time 
constants (i.e. time to 63% of the response) for each component. Goodness of fit was determined 
using three criteria: the coefficient of determination, sum of squared residuals, and visual 
inspection (Behnke et al., 2002). 
The mean response time (MRT1) was used to describe the overall dynamics of the PO2mv 
fall following the onset of muscle contractions via the equation: 
MRT1 = TD1 + τ1 
The MRT1 analysis was limited to the first component of the PO2mv response given that 
inclusion of an emergent second component underestimates the speed of the PO2mv fall at the 
onset of contractions. In the event of a second component the MRT2 was calculated using the 
following equation: 
MRT2 = TD2 + τ2 
To determine the overall time taken to reach the steady-state PO2mv the MRTTotal was 
calculated via the equation: 
MRTTotal = MRT1 + MRT2 
The MRTTotal does not equal the sum of the MRT1 and MRT2 averages because MRT2 is 
independent of the calculation of MRTTotal. The purpose of the second component kinetics 
parameters is to represent the speed with which the PO2mv(SS) is reached after the initial fall in 
PO2mv. For this reason, the MRT2 averages are calculated from rats with a two-component fit 
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only. However, the calculation of MRTTotal necessarily reflects the absence of MRT2 (i.e. 
effectively zero) for rats fit with a one-component model. 
 Statistical analysis 
MAP and HR were compared between conditions and across time points via 2-way 
repeated measures ANOVA.  The frequency of the PO2mv undershoot was determined via a chi-
squared test. All other results were compared between conditions with paired Student’s t-tests. 
The level of significance was set at p < 0.05. Results are presented as means ± SE. 
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 Results 
 Arterial blood samples and cardiovascular hemodynamics 
Arterial PO2, PCO2, O2 saturation, hematocrit and pH were not different between 
conditions (p > 0.05) which was also the case for arterial blood [lactate] (control: 1.4 ± 0.1, GLI: 
1.5 ± 0.2 mmol/L, p > 0.05) and [glucose] (control: 70 ± 7, GLI: 108 ± 17 mg/dL, p > 0.05). 
MAP was increased by GLI (Pre: 104 ± 4, Post: 121 ± 4 mmHg, p < 0.05) but not control 
infusion (Pre: 94 ± 5, Post: 96 ± 5 mmHg, p > 0.05). HR was not different with GLI (Pre: 348 ± 
15, Post: 339 ± 15 bpm, p > 0.05) or control infusion (Pre: 349 ± 7, Post: 352 ± 7 bpm, p > 0.05). 
 Spinotrapezius PO2mv 
There was no difference in PO2mv between pre- and post-GLI or pre- and post-control 
(p > 0.05; Fig. 1). However, GLI (Pre: 33.3 ± 1.7, Peak: 40.2 ± 1.5 mmHg, p < 0.05) but not 
control (Pre: 33.8 ± 2.0, Peak: 35.0 ± 2.2 mmHg, p > 0.05) caused a transient increase in 
spinotrapezius PO2mv that returned to baseline by 180 s (Fig. 1). Neither baseline nor steady-
state contracting spinotrapezius PO2mv were different with GLI infusion (Table 1). During the 
control condition 2 of 12 rats exhibited PO2mv profiles that transiently fell below the contracting 
steady-state (termed an “undershoot”, Δ2PO2mv) necessitating a two-component model fit. 
Conversely, during GLI the two-component model was required for 7 of 12 rats. The goodness 
of fit for the two-component model was not different for r2 (control: 0.98 ± 0.01, GLI: 0.98 ± 
0.00, p > 0.05) or the sum of squared residuals (control: 19.0 ± 5.9, GLI: 23.0 ± 7.0, p > 0.05) 
between conditions. The individual changes in Δ2PO2mv for these rats are highlighted in Figure 
2B demonstrating the values during control and GLI trials. Note the increase in the magnitude of 
GLI Δ2PO2mv for the two rats with undershoots present in the control condition. Using the 
control outcomes (2/12) as the expectation, a chi-squared analysis revealed that GLI increased 
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the frequency of an undershoot occurrence in PO2mv during contractions (p < 0.01). The 
undershoot magnitude as a percentage of both steady-state (control: 1.6 ± 1.1, GLI: 8.0 ± 2.6 %, 
p < 0.05) and the overall amplitude of the response (control: 2.3 ± 1.6, GLI: 15.6 ± 5.3 %, p < 
0.05) was greater with GLI (Fig. 2C). Furthermore, at the onset of contractions no parameters 
characterizing the fall in PO2mv were different between control and GLI (p > 0.05). However, 
due to the more pronounced undershoot the total MRT (MRTTotal; MRT1 + MRT2) was increased 
with GLI (control: 42.0 ± 14.2, GLI: 79.5 ± 14.7 s, p < 0.05). The result was a significant 
reduction in the mean PO2mv (p < 0.001) over the total duration of contractions which was 
particularly evident between 30 and 60 seconds (Δ: 1.2 ± 0.05 mmHg).  
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 Discussion 
These data indicate that, in contrast to our hypothesis, GLI does not speed the fall in 
PO2mv at the onset of contractions but does increase the occurrence of PO2mv undershoots 
wherein PO2mv falls initially below the steady state. At some 30-60 seconds of contractions a 
presumably more sluggish increase in QO2 concomitant with the mono-exponential rise in 
muscle VO2 (Behnke et al., 2002) drives PO2mv lower (~15% of the total amplitude) prior to the 
attainment of the steady state. This phenomenon affects the PO2mv profile by 1) nearly doubling 
the time to reach the steady state from the onset of contractions (i.e. MRTTotal; 190% of the 
control condition) and 2) further reducing the mean PO2mv, the magnitude of which represents a 
modest ~11% of the fall in PO2mv (Δ1PO2mv). The combination of an increased undershoot 
occurrence, increased overall mean response time, and reduced mean PO2mv with GLI suggests 
that the KATP channel regulates, in part, the PO2mv at the onset of contractions in healthy rat 
spinotrapezius muscle. Furthermore, the decrement in blood-myocyte O2 driving pressure 
coincides closely with the rapid, phase II rise in muscle VO2 which may contribute to a slowing 
of VO2 kinetics. 
 KATP channel inhibition and cardiovascular hemodynamics 
As expected the intra-arterial administration of GLI increased MAP and reduced HR 
compared to infusion of the vehicle. This robust increase in MAP has been shown to result from 
a decreased conductance in the renal and splanchnic vascular beds (Duncker et al., 2001; 
Holdsworth et al., 2015). The role of the KATP channel in setting basal vasomotor tone is well 
established and the inability of the baroreflex to prevent the GLI-induced rise in MAP supports 
the obligatory function of the KATP channel in systemic vascular control. Crucially, 
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administration of the vehicle did not significantly alter MAP which indicates a primary effect of 
GLI rather than a volume-loading response. 
 KATP channel inhibition and spinotrapezius PO2mv 
As seen in Figure 1 GLI infusion produced a transient increase in PO2mv which returned 
to pre-infusion levels such that baseline PO2mv was not different between conditions. This rise 
was coincident with a large increase in central driving pressure (i.e. % increase in MAP) due to 
vasoconstriction of quiescent tissue as described above. The ability to match O2 delivery to O2 
utilization after this brief transient (2-3 min) is not surprising given the redundant parallel 
pathways for skeletal muscle vasomotor control (e.g. NO, prostacyclin, baroreflex, myogenic 
control) to maintain appropriate O2 delivery, particularly at rest (Clifford and Hellsten, 2004). 
Indeed, measures of skeletal muscle blood flow at rest are unchanged with KATP channel 
inhibition for the rat (Holdsworth et al., 2015), pig (Duncker et al., 2001) and human (Farouque 
and Meredith, 2003) which is in line with the findings herein.  
The spinotrapezius PO2mv profiles herein are consistent with those demonstrated 
previously by our laboratory in healthy rats (Behnke et al., 2001). KATP channel manipulation of 
the steady-state QO2 has been characterized previously for in vivo electrical stimulations 
(Thomas et al., 1997), reactive hyperemia (Banitt et al., 1996; Bank et al., 2000; Bijlstra et al., 
1996) and exercise-induced hyperemia (Holdsworth et al., 2015). Our findings expand upon 
these investigations by demonstrating that, with GLI, the development of a PO2mv undershoot 
reduces the mean PO2mv during contractions and prolongs the overall time to achieve the 
contracting steady-state PO2mv. This reduced skeletal muscle PO2mv with GLI may impair 
blood-tissue O2 flux, decrease intracellular PO2 and elevate the accumulation of metabolites 
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implicated in fatigue (i.e. ADP, H+, Pi, K+) (Arthur et al., 1992; Hogan et al., 1992), thereby 
diminishing exercise tolerance (Grassi et al., 2015; Poole et al., 2012).  
The KATP channel inhibition may not have been complete and therefore the lower mean 
PO2mv and higher time to achieve steady-state PO2mv with GLI may be underestimated. The 
magnitude of the effect should also be considered in the context of varying skeletal muscle 
metabolic characteristics. The rat spinotrapezius demonstrates a mosaic fiber-type which is 
distributed approximately equally between low and high oxidative fiber types. Differential 
effects with KATP channel inhibition may be found across other more distinctly fiber-type 
compartmentalized muscles common to the rat. Our recent data suggests that the role of the KATP 
channel in muscle O2 delivery is fiber-type dependent with the GLI-induced reductions seen 
predominantly in highly oxidative muscles and muscle portions (Holdsworth et al., 2015). Thus, 
in mixed fiber-type muscles a less pronounced effect of KATP channel inhibition on the PO2mv 
profile may be observed, reinforcing the notion that a significant role for KATP channel function 
in exercise-induced hyperemia is driven by muscles with a dominant type I and IIa fiber 
composition. Despite the possible underestimation of effects due to these experimental 
considerations, the contraction-induced PO2mv profile with KATP channel inhibition does reflect 
a characteristic undershoot and prolonged recovery to the final contracting steady-state in the 
spinotrapezius which provides the closest translation to human locomotory muscle. This function 
of the KATP channel should not be underestimated given that the PO2mv undershoot and delayed 
steady state are well-defined in O2 supply-limited conditions such as heart failure (Ferreira et al., 
2006a), aging (Behnke et al., 2005) and diabetes mellitus (Padilla et al., 2007) which also present 
with severe exercise intolerance (Piepoli et al., 2010a, 2010b; Sacre et al., 2015).  
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The PO2mv undershoot has been attributed, in part, to reductions in NO-bioavailability 
(Ferreira et al., 2006a, 2006b). The parallel role of KATP channels and NO in manifesting the 
PO2mv undershoot highlights the plausible synergism between these two mediators of 
vasodilation. NO has been shown to cause arterial hyperpolarization, in part, via KATP channel 
activation (Murphy and Brayden, 1995) which may occur through the cGMP intermediary that 
elicits KATP channel activation in cardiac myocytes (Chai et al., 2011) and cultured smooth 
muscle cells (Kubo et al., 1994). Furthermore, as a reactive nitrogen species, NO can cause direct 
S-nitrosylation of cysteine residues found on the SURx subunit (Kawano et al., 2009; Yoshida et 
al., 2006), and channel activation via NO is likely mediated through a combination of the two 
mechanisms. The notion that KATP channels can act as an amplifier for NO and other vasoactive 
signals (Cole et al., 2000; Silva et al., 2008) via modulation of membrane potential deserves 
further investigation and may be valuable clinically (reviewed by Akrouh et al., 2009). 
 Implications for sulphonylurea therapy 
The schema presented herein is cause for concern given the use of sulphonylureas in the 
treatment of diabetes. Recently, the American College of Physicians has scrutinized the 
administration of sulphonylureas as a first-line monotherapy in diabetes, and the current 
treatment guidelines dictate that their use be reserved for cases where lifestyle modifications to 
diet and physical activity have proved ineffective (Qaseem et al., 2012). In support of this 
consensus, large retrospective studies revealed the associative risk of cardiovascular mortality 
and morbidity with sulphonylurea monotherapy (Fadini et al., 2015; Morgan et al., 2014; 
Simpson et al., 2006). In this regard, our findings demonstrate a significant peripheral vascular 
dysfunction with GLI which would be easily overlooked in the absence of overt cardiovascular 
disease (e.g. heart failure) or cardiovascular events (e.g. myocardial infarct, severe angina). 
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Interestingly, the reduced blood-myocyte O2 driving pressure appears to be time-aligned with the 
rapid phase II increase in muscle VO2 following the initiation of exercise (Behnke et al., 2002). 
The phase II muscle VO2 kinetics are significantly slowed in diabetic patients and an intriguing 
question is whether it is a diabetes- or sulphonlyurea-induced dysfunction of the KATP channel 
that is associated with the VO2 kinetics limitation (Bauer et al., 2007; O’Connor et al., 2015; 
Regensteiner et al., 1998). The answer is crucial for a diabetic population with compromised 
vascular function and reduced work capacity where an additional drag on O2 delivery could be 
the tipping point for patient quality of life. 
 Experimental considerations 
The exaggerated fall in skeletal muscle PO2mv at the onset of contractions is mediated by 
a non-proportional increase in the O2 delivery and utilization components of this ratio. 
Importantly, it must be considered whether a GLI-mediated increase in VO2 is plausible and, if 
so, whether it may be the principal driver of the PO2mv profile alterations seen herein. Despite 
the absence of a specific mitochondrial KATP channel blocker, the available evidence in vivo 
suggests that there is no change in VO2 during whole body exercise (Larsen et al., 1999) with 
GLI and that mitochondrial KATP channel inhibition, either at rest or during exercise, does not 
impact the O2 cost of contractions per se (Chen et al., 2001). Importantly, reductions in 
myocardial O2 consumption with GLI are driven by the interruption of blood flow and thus a 
local O2 insufficiency rather than a primary effect of mitochondrial KATP channel inhibition 
(Duncker et al., 2001). Based upon the evidence that PO2mv effects were not due to changes in VO2 evaluating the mechanisms for GLI to impact QO2 is warranted. 
The administration of GLI in vivo precludes the partitioning of the effects to either the 
endothelial or smooth muscle cells. In the case of the endothelium it remains to be clarified 
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whether hyperpolarization impacts vasomotor tone via NO release or propagated 
hyperpolarization to the smooth muscle (conducted vasodilation). Nonetheless, the inhibition of 
vascular smooth muscle and endothelial KATP channels, separately or in conjunction, leads to the 
conclusion that the KATP channel contributes to the temporal regulation of skeletal muscle 
PO2mv during contractions. 
It appears unlikely that GLI-induced KATP channel inhibition in the coronary vasculature 
or cardiac myocytes could account for the reduced BF during exercise given that a GLI-induced 
decrement in cardiac output would be expected to exhibit a homogenous spatial effect on muscle 
blood flow and vascular conductance. In contrast to this expectation, we have demonstrated 
previously that the reduction of total hindlimb skeletal muscle blood flow during exercise is 
driven by attenuations in the muscles comprised of a primarily type I and IIa fibers (Holdsworth 
et al., 2015). Furthermore, these results were seen at multiple intensities of large muscle mass 
exercise whereas contractions in the relatively small muscle-mass spinotrapezius of healthy rats 
will not tax the upper limits of cardiac output. This is supported by average heart rates during 
spinotrapezius contractions at ~62% of the HRmax for sedentary Sprague-Dawley rats (Hilty et 
al., 1989). 
We consider it unlikely that increased sympathetic nerve discharge via neuronal KATP  
channel inhibition would account for the reduced mean muscle PO2mv seen herein because it has 
been demonstrated, in male Sprague-Dawley rats, that direct injection of GLI into the rostral 
ventrolateral medulla has no effect on blood pressure, HR or renal SNA (Guo et al., 2011). These 
findings support that GLI did not directly impact sympathetic nerve discharge in the current 
study and that the PO2mv undershoot results specifically from muscle vascular KATP channel 
inhibition. 
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 Conclusions 
This investigation reveals a GLI-induced PO2mv undershoot following the onset of 
contractions in the rat spinotrapezius, resulting in a delayed attainment of the contracting steady-
state PO2mv and reduced mean PO2mv (evident most markedly from 30-60 s after the onset of 
contractions, Fig. 2A). The perturbed PO2mv kinetics with GLI, despite the presence of 
redundant vasomotor control, suggests a role for the KATP channel in mobilizing the appropriate QO2 response to maintain normal blood-myocyte O2 driving pressure across metabolic 
transitions. This effect raises the question of whether muscle vascular KATP channel dysfunction 
underlies, in part, the VO2 kinetics limitations of clinical populations with heart failure and/or 
diabetes. 
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Table 3-1. Spinotrapezius PO2mv parameters at rest and following the onset of 
contractions under control and GLI (5 mg/kg) conditions. 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Values are mean ± SE. PO2mv(BL), resting PO2mv; Δ1PO2mv, amplitude of the first component; Δ2PO2mv, amplitude 
of the second component; ΔTotalPO2mv, overall amplitude; PO2mv(SS), contracting steady-state PO2mv; TD1, time 
delay of the first component; TD2, time delay of the second component; τ1, time constant of the first component; τ2, 
time constant of the second component; MRT1, mean response time of the first component; MRT2, mean response 
time of the second component; MRTTotal, sum of the first and second component mean response times. One-
component exponential model used for 2/12 control and 7/12 GLI. All second component parameters calculated 
only from two-component models (control n = 2, GLI n = 7). * p < 0.05 vs. control. 
 
 
 
 
 
	 Control	 GLI	
PO2mv(BL),	mmHg	 34.0	±	2.2	 33.7	±	1.6	
Δ1PO2mv,	mmHg	 -10.8	±	1.0	 -12.3	±	1.0	
Δ2PO2mv,	mmHg	 1.8	±	0.2	 3.3	±	0.7	
ΔTotalPO2mv,	mmHg	 -10.5	±	1.0	 -10.4	±	1.1	
PO2mv(SS),	mmHg	 23.6	±	2.2	 23.4	±	1.9	
TD1,	s	 6.4	±	1.0	 7.2	±	1.3	
TD2,	s	 69.7	±	13.1	 63.0	±	11.5	
τ1,	s	 13.9	±	1.4	 16.6	±	1.7	
τ2,	s	 60.4	±	27.4	 32.6	±	7.5	
MRT1,	s	 20.3	±	1.7	 23.7	±	2.2	
MRT2,	s	 130.1	±	14.3	 95.6	±	8.9	
MRTTotal	 42.0	±	14.2	 79.5	±	14.7*	
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Figure 3-1. Spinotrapezius PO2mv averages for 180 s post-control (open circles) and post-
GLI (closed circles) infusion. The peak PO2mv was significantly greater with GLI but not 
control. 
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Figure 3-2. Spinotrapezius PO2mv profiles and kinetics representations. 
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(A) Representative spinotrapezius PO2mv profile for control (open circles) and GLI (closed circles). 180 s of 
contractions began at time zero. Note the divergence of PO2mv and manifestation of the undershoot after ~20 s. (B) 
Individual Δ2PO2mv (undershoot) responses to GLI. (C) The Δ2PO2mv (undershoot) as a function of both the steady 
state (first grouping) and total amplitude (second grouping) * p < 0.05 vs control. 
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Chapter 4 - Vascular KATP channels reduce severe muscle O2-
delivery to O2-utilization mismatch during contractions in chronic 
heart failure rats 
 Abstract 
The vascular ATP-sensitive K+ (KATP) channel is a mediator of skeletal muscle 
microvascular O2 delivery (PO2mv) during contractions. The objective was to test the hypothesis 
that KATP channel inhibition would augment the PO2mv undershoot, increase the time to reach 
the steady-state PO2mv and decrease the mean PO2mv during contractions of the spinotrapezius 
muscle in chronic heart failure rats. Muscle PO2mv (phosphorescence quenching) was measured 
during 180 s of 1-Hz twitch contractions (~6 V) under control, glibenclamide (5 mg/kg) and 
pinacidil (PIN; 5 mg/kg) conditions in 16 Sprague-Dawley rats with heart failure induced via 
myocardial infarction (coronary artery ligation). Glibenclamide increased the undershoot 
(control: 2.3 ± 0.4, GLI: 4.1 ± 0.5 mmHg, p < 0.05), reduced baseline (control: 28.3 ± 0.9, GLI: 
24.8 ± 1.0 mmHg p < 0.05) and mean PO2mv (control: 20.6 ± 0.6, GLI: 17.6 ± 0.3 mmHg, p < 
0.05), and slowed the attainment of steady-state PO2mv. PIN reversed the effects of GLI on the 
baseline PO2mv, undershoot, mean PO2mv and time to reach the steady state PO2mv (p < 0.05 
for all). Inhibition of KATP channels exacerbates the transient mismatch of O2-delivery to O2-
utilization in heart failure rats and can be reversed by PIN. These data suggest that the muscle 
hypoxia in heart failure augments the role of KATP channels in attenuating the decrease in muscle 
O2-delivery to O2-utilization matching at the onset of contractions. 
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 Introduction 
Oxygen transfer to peripheral tissues via both convective and diffusive routes is routinely 
interrupted as part of the inexorable progression of chronic, congestive heart failure (rev. by 
Poole et al., 2012). A growing, but likely incomplete list of this dysfunction now includes 
decrements in skeletal muscle blood flow and vascular conductance, lowering of the muscle 
microvascular O2 pressure (PO2mv), and derangement of capillary structure, geometry and 
hemodynamics (rev. by Piepoli et al., 2010a, 2010b). As a result of these effects, inadequate 
tissue O2 transport during the tremendous metabolic challenge imposed by exercise contributes 
to reductions in work capacity that are commensurate with the severity of heart failure (Miyazaki 
et al., 2007; Piepoli et al., 2010a, 2010b). For investigators interested in evaluating the 
dysfunction of cardiopulmonary control in general, and peripheral vascular control specifically, 
direct measurement of muscle PO2mv provides excellent insight because it represents the final 
pressure head responsible for blood-myocyte O2 diffusion. More importantly, because PO2mv is 
set by the ratio of O2-delivery to O2-utilization, and occurs at the terminal cell-to-cell interface of 
the O2 transport chain, it is impacted by upstream cardiopulmonary perturbations. This makes the 
PO2mv sensitive to both the spatial and temporal aspects of vascular function and accordingly it 
has been exploited in investigations of heart failure (Diederich et al., 2002) and nitric oxide (NO) 
function (Ferreira et al., 2006b). 
Maintaining adequate muscle PO2mv by tightly matching O2-supply to O2-demand is 
crucial given that even transient mismatch can cause a premature decline in muscle PCr stores 
and the accumulation of muscle metabolites associated with fatigue such as ADP, H+, K+ and Pi 
(Hogan et al., 1992; Richardson et al., 1995; Wilson et al., 1977). A potassium channel with 
sensitivity to ATP and ADP (KATP) suggests a potential transducer between tissue metabolism 
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and cell membrane potential via K+ efflux-induced hyperpolarization. A channel with these 
properties in vascular smooth muscle cells presents a unique mechanism for coupling vascular 
tone, and thus O2 availability, directly to skeletal muscle metabolism. It is readily evident that the 
KATP channel can function this way in vivo as inhibition exaggerates baroreflex-mediated 
vasoconstriction (Keller et al., 2004) and activation attenuates α-adrenergic vasoconstriction 
(Nakai and Ichihara, 1994; Tateishi and Faber, 1995). It remains unclear, however, under which 
circumstances the channel is obligatory to adequate skeletal muscle O2 transport. Individual 
studies of KATP channel inhibition are equivocal; some demonstrating robust effects on the 
magnitude of the hyperemic response at steady-state (Banitt et al., 1996; Bank et al., 2000; 
Bijlstra et al., 1996; Holdsworth et al., 2015) while others find no change (Duncker et al., 2001; 
Farouque and Meredith, 2003; Schrage et al., 2006). However, properties of the local micro-
environment are crucial to the role of the channel in vivo and will differ between species, disease 
states and events of cell stress (e.g. exercise) . In particular, KATP channel function is likely a 
requisite response to ischemia and thus cell hypoxia (Bijlstra et al., 1996; Nakai and Ichihara, 
1994; Suzuki et al., 2002; Tateishi and Faber, 1995; Wheaton and Chandel, 2011). Relative to 
healthy individuals these are primary attributes of muscle tissue in heart failure as discussed 
above. Therefore, the purpose of the study was to test the hypothesis that inhibition of vascular 
KATP channels via glibenclamide (GLI) would increase both the magnitude of the PO2mv 
undershoot and overall time to reach the contracting steady-state PO2mv in the spinotrapezius 
muscle of heart failure rats. Additionally, it was anticipated that these perturbations would drive 
a reduction in the mean PO2mv during the transition to steady-state PO2mv and that the effects of 
GLI would be reversed by the KATP channel activator pinacidil (PIN). 
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 Methods 
 Ethical approval 
All procedures were approved by the Institutional Animal Care and Use Committee of 
Kansas State University under the guidelines established by the National Institutes of Health. 16 
adult male Sprague-Dawley rats (3-6 months old) were maintained in accredited animal facilities 
(Association for the Assessment and Accreditation of Laboratory Animal Care) at Kansas State 
University on a 12-h light/12-h dark cycle with food and water provided ad libitum. 
 Myocardial infarction procedures 
All rats underwent induction of a myocardial infarction (MI) via ligation of the left main 
coronary artery which has been shown to result reliably in the development of chronic, 
congestive heart failure (Musch and Terrell, 1992).  Briefly, each rat (~275 g) was anesthetized 
with a gas mixture of 5% isoflurane-O2 and intubated for mechanical ventilation on a rodent 
respirator (model 680, Harvard Instruments, Holliston, USA) with subsequent maintenance on a 
3% isoflurane-O2 gas mixture for the duration of the procedure.  A left thoracotomy was 
performed to expose the heart through the fifth intercostal space.  Exteriorization of the heart 
provided access to the left main coronary artery which was ligated with a 6-0 silk suture ~1-2 
mm distal to the edge of the left atrium.  The muscles of the thorax were then closed with 4-0 
gut, and the skin incision was closed with 3-0 silk followed by an administration of the analgesic 
agents bupivacaine (1.5 mg·kg-1 subcutaneously) and buprenorphine (0.01–0.05 mg·kg-1 i.m.) as 
well as ampicillin (50 mg·kg-1 i.m.) to reduce the risk of infection.  Upon removal from 
mechanical ventilation and withdrawal of anesthesia the rats were monitored ~8-12 h post-
operatively for the development of arrhythmias and undue stress with care administered as 
needed.  The recovery duration prior to the final, PO2mv protocol was ≥21 days which is 
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consistent with the time course for complete remodeling of necrotic myocardial tissue (Fishbein 
et al., 1978).  During this time the rats were monitored daily (appetite, weight loss, gait/posture, 
etc.) in conjunction with the university veterinary staff. 
 Surgical instrumentation 
On the day of the final protocol the rats were anesthetized initially with a 5% isoflurane-
O2 mixture and maintained on a 3% isoflurane-O2 mixture for the duration of the surgical 
instrumentation. The carotid artery was cannulated and a two-French-catheter-tipped pressure 
transducer (Millar Instruments, Houston, USA) was advanced into the left ventricle (LV) for the 
measurement of left ventricular end diastolic pressure (LVEDP).  Subsequently, cannulation of 
both the carotid and caudal arteries was performed with PE-10 connected to PE-50 (Intra-Medic 
polyethylene tubing, Clay Adams, Spark, USA) for the measurement of mean arterial pressure 
(MAP) and heart rate (HR) as well as infusion of the phosphorescent probe G2 (carotid) and for 
blood sampling and administration of anesthetics (caudal). Isoflurane-O2 inhalation was 
progressively removed as anesthesia was maintained with pentobarbital sodium administered via 
the caudal artery catheter to effect. Depth of anesthesia was monitored at frequent and regular 
intervals via the blink and toe-pinch reflexes as well as magnitude and frequency of ventilation. 
Access to the spinotrapezius was achieved by surgically reflecting the overlying skin and fascia. 
The spinotrapezius muscle was selected because the fiber-type composition and oxidative 
capacity closely resembles that of the human quadriceps muscle group which makes it a useful 
analog of human locomotor muscle (Delp and Duan, 1996). During both the surgical preparation 
and experimental protocol the muscle was superfused frequently with Krebs-Hensleit 
bicarbonate-buffered solution consisting of (in mM) 4.7 KCl, 2.0 CaCl2, 2.4 MgSO4, 131 NaCl, 
and 22 NaHCO3 equilibrated with 5% CO2 and 95% N2 (pH 7.4, 37-
69 
surrounding the spinotrapezius muscle was covered with Saran wrap (Dow Brands, Indianapolis, 
IN) to reduce dehydration and limit the exposure of GLI and PIN to the spinotrapezius. Stainless 
steel electrodes were sutured to the rostral (cathode) and caudal (anode) regions of the 
spinotrapezius muscle for electrically-induced twitch contractions. As previously reported by our 
laboratory these surgical procedures do not impact the microvascular integrity and 
responsiveness of the rat spinotrapezius muscle (Bailey et al., 2000). 
 Drugs 
The pharmacological sulphonylurea derivative GLI (494 g mol-1; 5-chloro-N-(4-[N-
(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-2-methoxybenzamide; Sigma-Aldrich, St Louis, 
MO, USA) was used to inhibit vascular KATP channels. Given that GLI is difficult to maintain in 
solution, 25 mg of GLI was dissolved in 99:1 ratio of distilled water/NaOH (1 M) during 
continuous sonication to produce a 2.5 mg ml-1 stock solution. A 5 mg kg-1 dose was drawn from 
the stock solution and diluted to ~3 ml with Krebs-Hensleit solution. It has been reported 
previously that GLI is a selective KATP channel blocker at concentrations below 5 µmol L-1 
(Beech et al., 1993; Sadraei and Beech, 1995). The current dose of 5 mg kg-1 for rats of a mean 
body mass of 463 g equates to a blood concentration of ~140 µmol L-1. Given that 98-99% of 
GLI is bound to plasma protein, the effective blood concentration of GLI is ~2-3 µmol L-1 
(George et al., 1990) which is in the range for GLI to be selective for KATP channels without 
inhibition of Ca+ channel current (Sadraei and Beech, 1995). This dosing strategy, based on 
smooth muscle cell investigations, was shown to elicit a degree of KATP channel blockade for 
swine in vivo (Duncker et al., 2001). See Discussion for further considerations of KATP channel 
inhibition. PIN (245 g mol-1,N-cyano-N'-pyridin-4-yl-N''-(1,2,2-trimethylpropyl)guanidine; 
Sigma-Aldrich, St Louis, MO, USA) is readily dissolved in distilled water and was diluted to ~3 
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ml with Krebs-Hensleit solution before being administered to reverse vascular KATP channel 
inhibition at the same dose as GLI. 
 Experimental protocol 
Three separate contraction bouts were performed under control (vehicle), GLI (5 mg/kg) 
and PIN (5 mg/kg) conditions. The vehicle was administered for control via superfusion (3 ml) 
of the spinotrapezius during 180 s of continuous PO2mv recording. The recording was extended 
for an additional 90-180 s to ensure that baseline PO2mv had stabilized at which time muscle 
contraction was evoked via electrical stimulation (1 Hz, ~6 V, 2-ms pulse duration, model s48; 
Grass Technologies, Quincy, MA) for 180 s. This protocol has been shown to increase blood 
flow four- to five-fold and metabolic rate six- to seven-fold without altering blood pH and is 
consistent with moderate intensity exercise (Behnke et al., 2002; Hirai et al., 2013). Immediately 
upon cessation of electrical stimulation an arterial blood sample was drawn (~0.8 ml) for the 
determination of blood gases, hematocrit, pH, [lactate] and [glucose]. After a ~25 min recovery 
the second contraction bout was performed in an identical fashion to the first after the 
administration of GLI (5 mg/kg). This was repeated for the third contraction bout with the 
administration of PIN. As previously reported by our laboratory, >20 min recovery elicits 
reproducible PO2mv responses (Copp et al., 2009; Herspring et al., 2008). At the end of the 
protocol, rats were euthanized with intra-arterial pentobarbital sodium overdose (>50 mg/kg) and 
subsequent removal of the heart. The lungs, right ventricle (RV), LV and atria were separated 
and weighed. Measurement of infarct size in the LV was made via planimetry as described 
previously (Ferreira et al., 2006a). 
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 Spinotrapezius PO2mv measurement 
PO2mv was measured via phosphorescence quenching using a frequency domain 
phosphorometer (PMOD 5000; Oxygen Enterprises, Philadelphia, PA). As described previously 
(Behnke et al., 2001), this technique applies the Stern-Volmer relationship (Rumsey et al., 1988), 
which describes the quantitative O2 dependence of the phosphorescent probe G2 via the 
equation: 
PO2mv = [(τ°/ τ) – 1]/(kQ · τ°) 
where kQ is the quenching constant and τ and τ° are the phosphorescence lifetimes at the 
ambient O2 concentration and in the absence of O2, respectively. For the phosphorescent probe 
G2, kQ is 273 mmHg-1 s-1 and τ° is 251 µs (Bodmer et al., 2012; Dunphy et al., 2002). These 
characteristics do not change over the physiological range of pH (~7.4) and temperature (~38°C) 
in vivo and, therefore, the phosphorescence lifetime is affected solely by the O2 partial pressure. 
The Pd-porphyrin cores of phosphor probes bind to albumin; the primary macromolecule in 
plasma. This quality as well as the probes’ negative charge ensures restriction to the vascular 
compartment, of which, the capillary bed volumetrically constitutes the major intramuscular 
space (Poole et al., 2004). After infusion of G2 the common end of the bifurcated light guide 
with a >500 µm penetration depth was positioned ~2-4 mm superficial to the dorsal surface of 
the exposed spinotrapezius muscle in an area devoid of macro-vessels. The phosphorometer 
modulates sinusoidal excitation frequencies between 100 Hz and 20 kHz and allows 
phosphorescence lifetime measurements from 10 µs to ~2.5 ms. PO2mv was measured 
continuously and recorded at 2-s intervals throughout the duration of the experimental protocol. 
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 Analysis of spinotrapezius PO2mv kinetics 
PO2mv time course was determined via exponential regression analysis by applying the 
Levenberg-Marquardt algorithm (SigmaPlot 11.0; Systat software, San Jose, CA) to the 
contraction-induced PO2mv transient. The sum of squared residuals was used to indicate the 
appropriateness of the model fit. PO2mv responses were fit with either a one- or two-component 
model as follows. 
One component: 
PO2mv(t) = PO2mv(BL) – ΔPO2mv (1 – e - (t - TD) / τ) 
Two component: 
PO2mv(t) = PO2mv(BL) – Δ1PO2mv (1 – e - (t – TD1) / τ1) + Δ2PO2mv (1 – e - (t – TD2) / τ2) 
PO2mv(t) is the PO2mv at a given time t; PO2mv(BL) corresponds to the pre-contracting 
resting PO2mv; Δ1 and Δ2 are the amplitudes for the first and second components, respectively; 
TD1 and TD2 are the independent time delays for each component; and τ1 and τ2 are the time 
constants (i.e. time to 63% of the response) for each component. Goodness of fit was determined 
using three criteria: the coefficient of determination, sum of squared residuals, and visual 
inspection (Behnke et al., 2002). 
The mean response time (MRT1) was used to describe the overall dynamics of the PO2mv 
fall following the onset of muscle contractions via the equation: 
MRT1 = TD1 + τ1 
The MRT1 analysis was limited to the first component of the PO2mv response given that 
inclusion of an emergent second component underestimates the speed of the PO2mv fall at the 
onset of contractions. In the event of a second component the MRT2 was calculated using the 
following equation: 
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MRT2 = TD2 + τ2 
To determine the overall time taken to reach the steady-state PO2mv the MRT(Total) was 
calculated via the equation: 
MRTTotal = MRT1 + MRT2 
The MRT(Total) does not equal the sum of the MRT1 and MRT2 averages because MRT2 is 
independent of the calculation of MRT(Total). The purpose of the second component kinetics 
parameters is to represent the speed with which the PO2mv(SS) is reached after the initial fall in 
PO2mv. For this reason, the MRT2 averages are calculated from rats with a two-component fit 
only. However, the calculation of MRT(Total) necessarily reflects the absence of MRT2 (i.e. 
effectively zero) for rats fit with a one-component model. 
Mean PO2mv was calculated as the average PO2mv from the contractions onset through 
the duration of MRT(Total). 
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 Results 
The final body weight for all CHF rats was 463 ± 12 g. Table 1 summarizes the descriptive 
statistics for the central indices of CHF. Arterial blood [lactate], [glucose], PO2, PCO2, O2 
saturation, hematocrit and pH were not different with GLI relative to control and were not 
different after reversal of KATP channel inhibition with PIN (p > 0.05 for all). The MAP (control: 
110 ± 4, GLI: 114 ± 5, p > 0.05) and HR (control: 326 ± 10, GLI: 337 ± 14, p > 0.05) at the start 
of contractions with GLI was not different from control. PIN reduced MAP at the start of 
contractions compared to GLI (PIN: 100 ± 6, GLI: 114 ± 5 mmHg, p < 0.05), but did not change 
HR (PIN: 367 ± 14, GLI: 337 ± 14 mmHg, p > 0.05). 
The kinetics parameters are provided comprehensively in Table 2. During the control condition 
11 of 16 rats exhibited PO2mv profiles that transiently fell below the contracting steady-state 
(termed an “undershoot”, Δ2PO2mv) necessitating a two-component model fit. Conversely, 
during GLI the two-component model was required for 15 of 16 rats and during PIN for 11 of 12 
rats. The goodness of fit for the models was demonstrated by the excellent r2 (0.97 ± 0.005) and 
the sum of squared residuals (18.9 ± 3.0). Compared to control, GLI reduced the PO2mv baseline 
(CON: 28.3 ± 0.9, GLI: 24.8 ± 1.0 mmHg p < 0.05) and the amplitude of the the initial fall in 
PO2mv (∆1PO2mv). However, the amplitude as a function of the reduced baseline PO2mv was 
not different (control: 39 ± 2, GLI: 39 ± 2 %, p > 0.05). GLI increased the undershoot of the 
contracting steady-state (control: 2.3 ± 0.4, GLI: 4.1 ± 0.5 mmHg, p < 0.05), but there was no 
difference in the speed of the fall in PO2mv at the onset of contractions as indicated by the time 
delay, time constant and mean response time of the first component (τ1, TD1, and MRT1, 
respectively; p > 0.05 for all). GLI slowed the attainment of the steady state as indicated by an 
increase in the time constant and mean response time of the second component and total mean 
75 
response time (τ2, MRT2, and MRT(Total) respectively). The mean PO2mv (control: 20.6 ± 0.6, 
GLI: 17.6 ± 0.3 mmHg, p < 0.05) over the contraction transient was also reduced with GLI. 
Compared to GLI, PIN increased the PO2mv(BL) and PO2mv(SS) with no difference in the 
∆1PO2mv. PIN decreased the TD1, but did not change either the τ1 or MRT1 during the initial fall 
in PO2mv compared to GLI. PIN sped the attainment of the steady state by reducing the 
∆2PO2mv and thus MRT(Total) compared to GLI. The mean PO2mv (GLI: 17.6 ± 0.3, PIN: 25.7 ± 
0.5 mmHg, p < 0.05) over the contraction transient was increased compared to GLI. 
Given that PIN could not be compared to control all results were compared between conditions 
with paired Student’s t-tests on the basis of the a priori hypotheses. The level of significance was 
set at p < 0.05. Results are presented as means ± SE. 
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 Discussion 
KATP channel inhibition via GLI resulted in extensive perturbations of the spinotrapezius 
PO2mv profile at the onset of contractions in heart failure rats. The major effects of GLI were 1) 
a reduction in the baseline PO2mv 2) a near doubling of the PO2mv undershoot and 42% increase 
in the overall time to reach the contracting steady-state and 3) a reduced mean PO2mv during the 
transition from contraction onset to the steady-state PO2mv. GLI caused the PO2mv to 
undershoot the contracting steady-state by a remarkable ~60% of net amplitude compared to 
~20% in the control. Crucially, the mismatch of O2-delivery to O2-utilization coincides with the 
rapid phase II increase in VO2 kinetics (Behnke et al., 2002). Exacerbating the fall in skeletal 
muscle PO2mv due to a sluggish increase in QO2 is likely to impact cellular metabolism and may 
contribute to the slowing of VO2 kinetics in heart failure patients (Ferreira et al., 2005; Wheaton 
and Chandel, 2011; Wilson et al., 1977). These data suggest that vascular smooth muscle and/or 
endothelial KATP channel function are fundamental to the control of muscle PO2mv kinetics at 
the onset of contractions in heart failure, and the KATP channel may represent one of the few 
well-preserved mechanisms of skeletal muscle vascular control in heart failure. The KATP 
channel-induced protection against severe O2-delivery to O2-utilization mismatch during 
contractions raises serious concern when sulphonylureas such as GLI are prescribed for patients 
with coincident diabetes and heart failure. 
The central indices of dysfunction (Table 1) suggests that the severity of heart failure was 
moderate in these animals (Ferreira et al., 2006a). The spectrum included animals with LVEDP’s 
above 30 mmHg and MI size’s greater than 40% (severe heart failure) however the sample size 
was not sufficient for adequately powered statistical comparisons. Moderate heart failure induced 
via the rat model of coronary artery ligation results in decrements to skeletal muscle blood flow, 
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vascular conductance, PO2mv kinetics, VO2max, and time-to-exhaustion during exercise. 
However, the moderate heart failure herein may underestimate the effect of GLI on the PO2mv 
profiles during contractions. 
KATP channel manipulation of the steady-state QO2 has been characterized previously for 
in vivo electrical stimulation (Thomas et al., 1997), reactive hyperemia (Banitt et al., 1996; Bank 
et al., 2000; Bijlstra et al., 1996) and exercise-induced hyperemia (Holdsworth et al., 2015). Our 
laboratory has also demonstrated that GLI increased the prevalence of the undershoot and 
prolonged the time to reach the contracting steady-state PO2mv in the spinotrapezius of healthy 
rats (Holdsworth, pending). Conversely, the available evidence in vivo suggests that there is no 
change in VO2 during whole body exercise (Larsen et al., 1999) with GLI and that mitochondrial 
KATP channel inhibition does not impact the O2 cost of contractions (Chen et al., 2001). These 
data indicate that it is appropriate to interpret GLI-induced changes in QO2 as the primary driver 
of the perturbed PO2mv profile.  
The small-muscle mass preparation poses an advantage for investigations of peripheral 
vascular control because it does not tax the limits of cardiac output. This is fortunate for an 
investigation of KATP channel function in heart failure because the channel has a role in cardiac 
function. In heart failure rats it appears that the vascular KATP channel pathway remains intact 
given the marked sensitivity of the PO2mv profile to both GLI and PIN. The PO2mv profiles of 
the heart failure rats herein exhibit the characteristic undershoot demonstrated previously by our 
laboratory (Behnke et al., 2001; Hirai et al., 2014) and permitted the statistical comparison of 
second-component kinetics between control and GLI which has not been possible previously. It 
was revealed that the magnitude of the PO2mv undershoot was increased and the intrinsic speed 
of the second component, independent of the undershoot, was slowed by GLI. Mean PO2mv was 
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also lower across the metabolic transition and, in contrast to previous results in healthy rats, the 
baseline PO2mv was reduced with GLI. Our findings also extend upon previous investigations by 
demonstrating reversal of the major effects of GLI via PIN. The robust role of vascular KATP 
channels in heart failure is not surprising given the shift in metabolic phenotype towards a 
greater reliance on glycolytic pathways (Delp et al., 1997) and thus increased intracellular [ADP] 
(Hogan et al., 1992; Wilson et al., 1977). In addition, the loss of vasodilatory redundancy in heart 
failure (e.g. NO-bioavailability) is likely to increase reliance on the intact KATP channel pathway 
and these data are the first evidence to support the argument that the role of the KATP channel in 
vascular control can be masked by the ample hyperemic reserve in healthy conditions. 
GLI clearly exaggerates many of the heart-failure induced perturbations of skeletal 
muscle PO2mv kinetics including the PO2mv undershoot and prolonged recovery to the final 
contracting steady-state PO2mv (Ferreira et al., 2006a). This effect is also well-characterized in 
other O2 supply-limited conditions such as aging (Behnke et al., 2005) and diabetes (Padilla et 
al., 2007) which are often coincident conditions for heart failure patients. The exacerbation of 
this dysregulation with GLI is physiologically relevant given that these populations present with 
severe exercise intolerance (Piepoli et al., 2010a, 2010b; Sacre et al., 2015) due, in part, to 
inadequate regulation of the skeletal muscle PO2mv pressure head (rev. by Poole et al., 2012). 
Both the magnitude and timing (i.e. during the exponential rise in VO2) of the decrements in 
PO2mv also indicates that the perturbations of [metabolite] are likely to impair muscle work 
capacity and/or VO2 kinetics. 
The PO2mv undershoot has been attributed, in part, to reductions in NO-bioavailability 
(Ferreira et al., 2006a, 2006b) and the results herein indicate that the KATP channel protects 
against a severe mismatch of O2-delivery to O2-utilization. The shared contribution of attenuated 
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NO and KATP channel-mediated QO2 to the PO2mv undershoot suggests that these pathways are 
not merely independent, parallel mechanisms, but rather synergistic mediators of O2-delivery to 
O2-utilization matching. NO has been shown to cause arterial hyperpolarization, in part, via KATP 
channel activation (Murphy and Brayden, 1995) which may occur through the cGMP 
intermediary that elicits KATP channel activation in cardiac myocytes (Chai et al., 2011) and 
cultured smooth muscle cells (Kubo et al., 1994). Furthermore, as a reactive nitrogen species, 
NO can cause direct S-nitrosylation of cysteine residues found on the SURx subunit (Kawano et 
al., 2009; Yoshida et al., 2006), and channel activation via NO is likely mediated through a 
combination of the two mechanisms. The notion that KATP channels can act as an amplifier for 
NO and other vasoactive signals (Cole et al., 2000; Silva et al., 2008) via modulation of 
membrane potential deserves further investigation and may be valuable clinically (rev. by 
Akrouh et al., 2009). 
Both the results herein and large retrospective studies of the association of sulphonylurea 
monotherapy with cardiovascular mortality and morbidity are cause for concern in diabetic and 
heart failure patients (Fadini et al., 2015; Morgan et al., 2014; Simpson et al., 2006). Our 
findings demonstrate the additive effect of GLI on PO2mv dysregulation in heart failure which 
has been minimally addressed in the risk assessments of sulphonylurea therapy. The phase II 
muscle VO2 kinetics are significantly slowed in diabetic patients and an intriguing question is 
whether it is a diabetes- or sulphonlyurea-induced dysfunction of the KATP channel that is 
associated with the VO2 kinetics limitation (Bauer et al., 2007; O’Connor et al., 2015; 
Regensteiner et al., 1998). Clearly, when other pathways have been attenuated by heart failure 
the KATP channel remains one of the few defenses against a severe mismatch of O2-delivery to 
O2-utilization during contractions. The administration of sulphonylureas may pose a previously 
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unrecognized danger in patients afflicted with both heart failure and diabetes where an additional 
drag on O2 delivery could bring physical activity to a halt. 
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Table 4-1. Morphological and hemodynamic characteristics of CHF rats.	
	
	
	
	
	
	
Data are ± SEM. #, sample mean; X(1)	–	X(n),	sample	minimum	to	maximum;	LVEDP, left ventricular end 
diastolic pressure; LV dp/dt, left ventricular dpressure/dtime RV, right ventricle; LV, left ventricle. n = 16	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 #8 	 X(1)	–	X(n)	
LVEDP,	mmHg	 18	±	1	 10	–	27	
LV	dp/dt,	mmHg/s	 6270	±	239	 4900	–	8800	
LV/body	mass,	mg/g	 1.91	±	0.03	 1.73	–	2.07	
RV/body	mass,	mg/g	 0.59	±	0.02	 0.51	–	0.78	
Lung/body	mass,	mg/g	 3.56	±	0.16	 2.78	–	5.29	
Infarct	size,	%	 30	±	1	 18	-	42	
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Table 4-2. Spinotrapezius PO2mv parameters at rest and following the onset of 
contractions under control, GLI and PIN conditions. 
Values are mean ± SE. PO2mv(BL), resting PO2mv; Δ1PO2mv, amplitude of the first component; Δ2PO2mv, amplitude 
of the second component; PO2mv(SS), contracting steady-state PO2mv; TD1, time delay of the first component; TD2, 
time delay of the second component; τ1, time constant of the first component; τ2, time constant of the second 
component; MRT1, mean response time of the first component; MRT2, mean response time of the second 
component; MRTTotal, sum of the first and second component mean response times. One-component exponential 
model used for 11/16 control, 15/16 GLI and 11/12 PIN. All second component parameters calculated only from 
two-component models (control n = 11, GLI n = 15, PIN n = 11). * p < 0.05 vs. control. # p < 0.05 vs GLI 
 
 
 
 
 
 
 
	 Control	 GLI	 PIN	
PO2mv(BL),	mmHg	 28.3	±	0.9	 24.8	±	1.0*	 32.5	±	2.0#	
Δ1PO2mv,	mmHg	 11.0	±	0.7	 9.7	±	0.6*	 9.7	±	1.2	
Δ2PO2mv,	mmHg	 2.3	±	0.4	 4.1	±	0.5*	 1.0	±	0.4#	
PO2mv(SS),	mmHg	 19.6	±	0.6	 19.1	±	0.9	 23.8	±	1.4#	
TD1,	s	 5.5	±	0.9	 4.7	±	0.6	 3.0	±	0.7#	
TD2,	s	 39.0	±	6.9	 36.8	±	5.2	 57.0	±	12.7	
τ1,	s	 10.6	±	0.7	 10.3	±	1.0	 16.8	±	3.6	
τ2,	s	 33.6	±	4.6	 47.1	±	5.4*	 32.5	±	7.2	
MRT1,	s	 16.2	±	1.1	 15.0	±	1.0	 19.8	±	3.3	
MRT2,	s	 66.5	±	9.4	 83.9	±	6.3*	 89.5	±	12.2	
MRTTotal	 66.1	±	10.2	 93.6	±	7.8*	 57.1	±	14.1#	
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Figure 4-1. Spinotrapezius PO2mv profiles and kinetics representations. 
 
(Top panel) Absolute spinotrapezius PO2mv profiles of control (open circles) vs GLI (closed circles) and (middle 
panel) GLI vs PIN (open triangle). 180 s of contractions began at time zero. (Bottom panel) Relative PO2mv profiles 
of control, GLI and PIN. 
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Chapter 5 - Summary 
The collection of studies herein describes the role of the vascular KATP channel in 
regulating skeletal muscle O2 transport. The exploration includes varying exercise intensities, 
large muscle mass recruitment and discernment of fiber type heterogeneity across two powerful 
techniques that reflect spatial and temporal aspects of vascular control. Until now, the available 
data for KATP channel inhibition was limited by the redundancy of vasodilatory control and 
examined relatively benign exercise conditions. The characteristics of our exercise and disease 
(heart failure) paradigm investigated KATP channel function in a microenvironment likely to 
produce recruitment of the channel. The fiber type of the rat, the relative tissue hypoxia of heart 
failure and the greater demand on whole body oxygen utilization for treadmill running revealed 
previously unknown aspects of KATP channel function in matching skeletal muscle O2 delivery to 
O2 demand. Furthermore, the kinetics data presented a more complete description of this 
function by determining where the decrements in vascular function coincide with the exercise 
response which has been masked during steady-state investigations. 
In a broad sense these results are expected to contribute to the evidence-based clinical 
treatment of diabetes. Given the pervasiveness of diabetes in Western society, the solution to the 
root problem of glucose regulation is often single-mindedly pursued. Our data complements the 
epidemiology demonstrating the cardiovascular risks of sulphonylureas and suggests that 
treatment approaches need to be carefully prescribed. Importantly, I posit that a focus on the 
function of the individual (e.g. work capacity) is the best starting point for clinical treatment 
because it would retain focus on the parallels between the indicators of disease severity and the 
most effective treatment (i.e. exercise and diet). This would prevent the costly mismanagement 
of pharmacological intervention in diabetes patients with tremendous dysfunction of the exercise 
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response across multiple systems. Despite these results the function of the KATP channel in 
vascular control has not been comprehensively addressed. Our results correct a deficiency in the 
literature by generating hypotheses for clinical investigations of sulphonylurea use in both 
diabetic populations and combined diabetes-heart failure patients. Comparison of novel data to 
our hemodynamic evidence of glibenclamide use will permit the appropriate interpretation of 
future study designs. Thus, many previously intractable questions of vascular KATP channel 
function in diabetes can now be meaningfully addressed. 
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